

Dabigatran etexilate â€“ a novel, reversible, oral direct thrombin inhibitor: synthesis, pharmacology, pharmacokinetics, safety, efficacy in stroke prevention, myocardial infarction, venous thromboembolism, and reversal of anticoagulant activity

Thrombosis and Haemostasis

103, 1116-1127

DOI: 10.1160/th09-11-0758

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effect of the increasing use of coronary angioplasty on outcome at one year in patients with unstable angina.. Heart, 1995, 74, 680-684.	1.2	2
2	The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology, 2008, 51, 2075-2081.	1.2	4
4	Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management. Current Pharmaceutical Design, 2010, 16, 3436-3441.	0.9	83
5	Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thrombosis and Haemostasis, 2010, 104, 1263-1271.	1.8	326
7	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurology, The, 2010, 9, 1157-1163.	4.9	399
8	Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice. Acta Cardiologica, 2010, 65, 491-497.	0.3	7
9	Impact of race and gender on antithrombotic therapy. Thrombosis and Haemostasis, 2010, 104, 471-484.	1.8	68
10	Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1885-1889.	1.1	198
11	Dabigatran Inhibits <i>Staphylococcus aureus</i> Coagulase Activity. Journal of Clinical Microbiology, 2010, 48, 4248-4250.	1.8	43
12	Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants. Current Pharmaceutical Design, 2010, 16, 3478-3482.	0.9	9
13	Treatment of Venous Thromboembolism in Older People. Journal of Pharmacy Practice and Research, 2010, 40, 309-314.	0.5	0
14	Anticoagulant-Associated Intracerebral Hemorrhage. Seminars in Neurology, 2010, 30, 565-572.	0.5	105
15	Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 56, 2067-2076.	1.2	67
16	Anticoagulants: Newer Ones, Mechanisms, and Perioperative Updates. Anesthesiology Clinics, 2010, 28, 667-679.	0.6	8
17	Purification and characterization of Trimerin™ a hemorrhagic metalloprotease with factor Xa-like Activity, from Trimeresurus malabaricus snake venom. Thrombosis Research, 2010, 126, e356-e364.	0.8	12
18	Dabigatran Etxilate. American Journal of Cardiovascular Drugs, 2011, 11, 57-72.	1.0	36
19	Dabigatran etexilate: a guide to its use in the prevention of thromboembolic disorders. Drugs and Therapy Perspectives, 2011, 27, 1-8.	0.3	0
20	Thrombin as a multi-functional enzyme. Thrombosis and Haemostasis, 2011, 106, 1020-1033.	1.8	101

#	ARTICLE	IF	CITATIONS
21	Dabigatran Etxilate. <i>Circulation</i> , 2011, 123, 1436-1450.	1.6	340
22	Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate. <i>Circulation</i> , 2011, 124, 1573-1579.	1.6	1,352
23	Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient. <i>Advances in Surgery</i> , 2011, 45, 361-390.	0.6	2
24	Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 669-676.	0.7	164
25	Laboratory assessment of new anticoagulants. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 761-772.	1.4	149
26	<sc>H</sc>emostasis, coagulation, and complications. <i>Endodontic Topics</i> , 2011, 24, 4-25.	0.5	6
27	A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery. <i>Drug Safety</i> , 2011, 34, 449-463.	1.4	20
28	New anticoagulants: Moving on from scientific results to clinical implementation. <i>Annals of Medicine</i> , 2011, 43, 606-616.	1.5	9
29	Dabigatran Falsely Elevates Point of Care International Normalized Ratio Results. <i>American Journal of Medicine</i> , 2011, 124, e5-e6.	0.6	23
31	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Management of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department. <i>Canadian Journal of Cardiology</i> , 2011, 27, 38-46.	0.8	117
32	Dabigatran Etxilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease. <i>Annals of Pharmacotherapy</i> , 2011, 45, 603-614.	0.9	13
33	Dabigatran: A New Oral Anticoagulant. <i>Journal of Perianesthesia Nursing</i> , 2011, 26, 420-423.	0.3	1
34	Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement. <i>Thrombosis Research</i> , 2011, 127, 457-465.	0.8	157
35	Indicaciones del dabigatrÃn. <i>Semergen</i> , 2011, 37, 252-254.	0.2	3
36	Factor Xa and thrombin as targets for new oral anticoagulants. <i>Thrombosis Research</i> , 2011, 127, S5-S12.	0.8	64
37	Advances in Anticoagulation: Focus on Dabigatran, an Oral Direct Thrombin Inhibitor. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2011, 25, 1208-1212.	0.6	13
38	Clinical and basic science articles from Thrombosis and Haemostasis. <i>Thrombosis and Haemostasis</i> , 2011, 105, 202-205.	1.8	3
39	Prevention and Treatment of Venous Thromboembolic Events: Focus on Dabigatran Etxilate. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S1176.	0.4	0

#	ARTICLE	IF	CITATIONS
40	Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, 570.	2.0	17
41	Novos anticoagulantes em cuidados intensivos. <i>Revista Brasileira De Terapia Intensiva</i> , 2011, 23, 68-77.	0.1	4
42	Dabigatran and other oral antithrombotic agents for the prevention of stroke in patients with atrial fibrillation. <i>Research Reports in Clinical Cardiology</i> , 2011, , 71.	0.2	1
43	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
44	Some considerations about the hypercoagulable states and their treatments. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 155-159.	0.5	17
45	Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. <i>Blood</i> , 2011, 117, 3912-3920.	0.6	84
46	Liver Transplantation From Donors With Acute Intermittent Porphyria. <i>Annals of Internal Medicine</i> , 2011, 154, 571.	2.0	60
47	Antithrombotic Therapy in Atrial Fibrillation - Evaluation and Positioning of New Oral Anticoagulant Agents -. <i>Circulation Journal</i> , 2011, 75, 1539-1547.	0.7	53
48	Laboratory testing of anticoagulants: the present and the future. <i>Pathology</i> , 2011, 43, 682-692.	0.3	80
49	Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. <i>Thrombosis and Haemostasis</i> , 2011, 106, 178-179.	1.8	59
50	Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, 570.	2.0	7
52	Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, 570.	2.0	3
53	Direct thrombin inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 581-592.	1.1	209
54	New anticoagulants: how to deal with treatment failure and bleeding complications. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 593-603.	1.1	49
55	How do we manage patients treated with antithrombotic therapy in the perioperative interval. <i>Transfusion</i> , 2011, 51, 2066-2077.	0.8	7
56	New Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 948-955.	0.8	19
57	Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 12-19.	1.9	81
59	Double right coronary artery or conus artery with separate orifice?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 1288-1289.	0.4	1

#	ARTICLE	IF	CITATIONS
60	Dabigatran after cardiac surgery: Caution advised. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 1288.	0.4	8
62	Novel Oral Anticoagulants and Their Role in Clinical Practice. <i>Pharmacotherapy</i> , 2011, 31, 1175-1191.	1.2	37
63	Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness. <i>Pharmacotherapy</i> , 2011, 31, 1232-1249.	1.2	31
64	Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. <i>Thrombosis and Haemostasis</i> , 2011, 105, 371-378.	1.8	276
66	New oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 310-320.	1.0	52
67	New anticoagulants: pharmacology and clinical studies. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 54-57.	0.5	5
68	Monitoring of direct anticoagulants. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 58-62.	0.5	11
71	Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. <i>Advances in Therapy</i> , 2011, 28, 460-472.	1.3	15
72	Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant. <i>Journal of Medical Toxicology</i> , 2011, 7, 281-287.	0.8	115
73	Prediction of Stroke Risk in Atrial Fibrillation, Prevention of Stroke in Atrial Fibrillation, and the Impact of Long-Term Monitoring for Detecting Atrial Fibrillation. <i>Current Atherosclerosis Reports</i> , 2011, 13, 290-297.	2.0	9
74	Stroke Prevention in the High-risk Atrial Fibrillation Patient: Medical Management. <i>Current Cardiology Reports</i> , 2011, 13, 9-17.	1.3	6
75	Pharmacological basis and clinical evidence of dabigatran therapy. <i>Journal of Hematology and Oncology</i> , 2011, 4, 53.	6.9	15
76	Practical aspects of the oral new anticoagulants. <i>American Journal of Hematology</i> , 2011, 86, 586-590.	2.0	25
77	Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 1416-1425.	6.7	100
79	Discrepant results from laboratories impact patients receiving heparin or antithrombin therapy. <i>Biomarkers in Medicine</i> , 2011, 5, 211-218.	0.6	4
80	Routine preoperative coagulation tests: an outdated practice?. <i>British Journal of Anaesthesia</i> , 2011, 106, 1-3.	1.5	66
82	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ: British Medical Journal</i> , 2011, 342, c7270-c7270.	2.4	13
83	Antithrombotic Therapy for Secondary Stroke Prevention. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2011, 17, 1255-1266.	0.4	2

#	ARTICLE	IF	CITATIONS
84	Dabigatran. <i>Critical Pathways in Cardiology</i> , 2011, 10, 117-127.	0.2	11
85	Reversal of New Oral Anticoagulants. <i>Circulation</i> , 2011, 124, 1508-1510.	1.6	31
86	Periprocedural Management of Patients on Dabigatran Etxilate Treatment. <i>American Journal of Neuroradiology</i> , 2011, 32, E166-E166.	1.2	5
87	Anticoagulation With the Oral Direct Thrombin Inhibitor Dabigatran Does Not Enlarge Hematoma Volume in Experimental Intracerebral Hemorrhage. <i>Circulation</i> , 2011, 124, 1654-1662.	1.6	82
88	Potential Inaccuracy of Point-of-Care INR in Dabigatran-Treated Patients. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1025-1025.	0.9	36
89	Hospital-Based Clinical Implications of the Novel Oral Anticoagulant, Dabigatran Etxilate, in Daily Practice. <i>Hospital Practice (1995)</i> , 2011, 39, 23-34.	0.5	4
90	The Use of Dabigatran in Elderly Patients. <i>Archives of Internal Medicine</i> , 2011, 171, 1285.	4.3	186
91	Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran. <i>Stroke</i> , 2011, 42, 3594-3599.	1.0	334
92	Efficacy and safety of novel anticoagulants compared with established agents. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 175-195.	1.1	13
93	Dabigatran Etxilate. <i>Cardiology in Review</i> , 2011, 19, 154-161.	0.6	24
94	A New Landscape for Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2011, 42, 3316-3322.	1.0	26
95	Assessment of oral antithrombotic therapy by platelet function testing. <i>Nature Reviews Cardiology</i> , 2011, 8, 572-579.	6.1	21
96	Pros and cons of dabigatran. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1495-1495.	0.5	2
97	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. <i>European Heart Journal</i> , 2011, 32, 1968-1976.	1.0	61
98	Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. <i>BMJ: British Medical Journal</i> , 2011, 343, d6333-d6333.	2.4	137
99	Wound Problems following Hip Arthroplasty before and after the Introduction of a Direct Thrombin Inhibitor for Thromboprophylaxis. <i>HIP International</i> , 2011, 21, 678-683.	0.9	21
100	Direct Thrombin Inhibitor (Dti) vs. Aspirin in Primary Total Hip and Knee Replacement Using Wound Ooze as the Primary Outcome Measure. A Prospective Cohort Study. <i>HIP International</i> , 2012, 22, 22-27.	0.9	25
101	A 77-Year-Old Man with a Prolonged Activated Partial Thromboplastin Time. <i>Clinical Chemistry</i> , 2012, 58, 1402-1405.	1.5	1

#	ARTICLE	IF	CITATIONS
102	Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists. <i>Circulation</i> , 2012, 126, 1630-1639.	1.6	406
103	High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: A case report and review of laboratory considerations. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 490-495.	0.5	15
104	Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. <i>Heart</i> , 2012, 98, 1404-1406.	1.2	22
105	Periprocedural Bridging Management of Anticoagulation. <i>Circulation</i> , 2012, 126, 486-490.	1.6	73
106	Newer Anticoagulants in Cardiovascular Disease. <i>Cardiology in Review</i> , 2012, 20, 209-221.	0.6	24
108	Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1646-1650.	0.5	61
109	New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 165-170.	1.6	65
110	Dabigatran. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 237-247.	1.0	7
111	Dabigatran (Pradaxa). <i>American Journal of Neuroradiology</i> , 2012, 33, 426-428.	1.2	11
113	Determination of Dabigatran in Human Plasma Samples. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 16-22.	1.5	73
114	Emerging Anticoagulant Therapies for Atrial Fibrillation: New Options, New Challenges. <i>Current Medicinal Chemistry</i> , 2012, 19, 4688-4698.	1.2	7
115	Approaches to Diagnosing and Managing Anticoagulant-Related Bleeding. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 702-710.	1.5	14
116	Preventing Venous Thromboembolic Events After Total Hip Arthroplasty: New Developments in Clinical Practice. <i>Hospital Practice (1995)</i> , 2012, 40, 79-87.	0.5	6
117	Periprocedural Anticoagulant Management. <i>Hospital Practice (1995)</i> , 2012, 40, 40-49.	0.5	2
118	More on Acutely Injured Patients Receiving Dabigatran. <i>New England Journal of Medicine</i> , 2012, 366, 863-864.	13.9	5
119	Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2012, 366, 861-863.	13.9	3
120	Active Online Assessment of Patients Using New Oral Anticoagulants: Bleeding Risk, Compliance, and Coagulation Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 23-30.	1.5	48
121	New Anticoagulants in the Treatment of VTE. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 191-198.	0.8	2

#	ARTICLE	IF	CITATIONS
123	Laboratory Identification of Lupus Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 375-384.	1.5	46
125	The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 07-15.	1.5	17
126	Target-Specific Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation: Real-World Considerations. <i>Hospital Practice (1995)</i> , 2012, 40, 50-57.	0.5	0
127	Transitions of Care in Anticoagulation Management for Patients with Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 2012, 40, 20-27.	0.5	1
128	Practical Management of Anticoagulants in Family Medicine after Orthopedic Surgery. <i>Postgraduate Medicine</i> , 2012, 124, 206-214.	0.9	1
129	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695.	2.9	71
130	Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. <i>Heart</i> , 2012, 98, 573-578.	1.2	106
131	Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1087-1090.	0.9	1
132	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1471-1480.	0.6	42
133	Rectal Bleeding and Hemostatic Disorders Induced by Dabigatran Etexilate in 2 Elderly Patients. <i>Annals of Pharmacotherapy</i> , 2012, 46, e14-e14.	0.9	32
134	Fatal gastrointestinal hemorrhage after a single dose of dabigatran. <i>Clinical Toxicology</i> , 2012, 50, 571-573.	0.8	41
135	Dabigatran Use in a Postoperative Coronary Artery Bypass Surgery Patient with Nonvalvular Atrial Fibrillation and Heparin-PF4 Antibodies. <i>Annals of Pharmacotherapy</i> , 2012, 46, e3-e3.	0.9	11
136	Safe Use of Hemodialysis for Dabigatran Removal before Cardiac Surgery. <i>Annals of Pharmacotherapy</i> , 2012, 46, e21-e21.	0.9	69
137	Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. <i>Circulation</i> , 2012, 126, 2428-2432.	1.6	105
138	Bridging Evidence-Based Practice and Practice-Based Evidence in Periprocedural Anticoagulation. <i>Circulation</i> , 2012, 126, 1573-1576.	1.6	52
139	Stroke Prevention in Atrial Fibrillation: Where are We Now?. <i>Clinical Medicine Insights: Cardiology</i> , 2012, 6, CMC.S8976.	0.6	9
140	Significant Bleeding in Elderly Patient with Atrial Fibrillation Due to Probable Interaction between Dabigatran and Amiodarone. <i>Journal of Pharmacy Technology</i> , 2012, 28, 139-145.	0.5	1
141	Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1601-5.	1.4	57



#	ARTICLE	IF	CITATIONS
142	Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation. <i>Pharmaceuticals</i> , 2012, 5, 155-168.	1.7	7
143	Spontaneous ascending aortic intramural haematoma in a patient on dabigatran. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2012, 15, 299-300.	0.5	15
144	Dabigatran etexilate tetrahydrate. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2012, 68, o3385-o3385.	0.2	3
145	Is Dabigatran Cost Effective Compared With Warfarin for Stroke Prevention in Atrial Fibrillation?. <i>Neurologist</i> , 2012, 18, 102-107.	0.4	17
146	Promise and challenges of anticoagulation with dabigatran. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 336-338.	1.4	5
147	Novel anticoagulants in atrial fibrillation stroke prevention. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 123-136.	1.1	16
148	Position paper on laboratory testing for patients taking new oral anticoagulants. <i>Consensus Medicine</i> , 2012, 50, 2137-2140.	1.4	23
149	Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2012, 43, 3442-3453.	1.0	248
150	Letter by Moll Regarding Article, "Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran". <i>Stroke</i> , 2012, 43, e24; author reply e25.	1.0	1
151	Letter by Freeman et al Regarding Article, "Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial". <i>Stroke</i> , 2012, 43, e63.	1.0	2
152	Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 43-56.	1.5	12
153	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012, 14, 8-27.	0.7	193
154	Dabigatran: Uncharted Waters and Potential Harms. <i>Annals of Internal Medicine</i> , 2012, 157, 66.	2.0	26
155	Dabigatran: laboratory monitoring. <i>Pathology</i> , 2012, 44, 578-580.	0.3	9
156	Application of the RELY Study to Lifetime Risks of Atrial Fibrillation. <i>Neurosurgery</i> , 2012, 70, N10-N11.	0.6	0
157	Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. <i>Current Cardiology Reviews</i> , 2012, 8, 290-301.	0.6	12
158	Newer Oral Anticoagulant Agents: A New Era in Medicine. <i>Current Cardiology Reviews</i> , 2012, 8, 158-165.	0.6	14
159	Atrial Fibrillation in Acute ST-Elevation Myocardial Infarction: Clinical and Prognostic Features. <i>Current Cardiology Reviews</i> , 2012, 8, 281-289.	0.6	25

#	ARTICLE	IF	CITATIONS
160	A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2012, 107, 775-785.	1.8	40
161	Management of dabigatran-induced anticoagulation in trauma and acute care surgery patients. <i>Journal of Trauma and Acute Care Surgery</i> , 2012, 73, 1064-1069.	1.1	10
163	New anticoagulants. <i>Journal of Trauma and Acute Care Surgery</i> , 2012, 73, 983-992.	1.1	28
164	Epidural Hematoma and Intraoperative Hemorrhage in a Spine Trauma Patient on Pradaxa (Dabigatran). <i>Spine</i> , 2012, 37, E863-E865.	1.0	48
165	Anticoagulant therapy. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 482-493.	0.5	25
166	Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 138-143.	0.5	248
168	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1009-1022.	1.8	65
169	Dabigatran etexilate for the prevention of stroke in patients with nonvalvular atrial fibrillation. <i>Clinical Practice (London, England)</i> , 2012, 9, 629-637.	0.1	0
170	A New Era of Antithrombotic Therapy in Patients With Atrial Fibrillation. <i>American Journal of the Medical Sciences</i> , 2012, 344, 128-135.	0.4	2
171	Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. <i>Blood</i> , 2012, 119, 1248-1255.	0.6	103
172	Efficacy and Safety of Periprocedural Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation. <i>Circulation Journal</i> , 2012, 76, 2337-2342.	0.7	85
173	Pulmonary embolism: risk assessment and management. <i>European Heart Journal</i> , 2012, 33, 3014-3022.	1.0	118
174	Forty Years in Academic Cardiology. <i>Cardiology in Review</i> , 2012, 20, 265-267.	0.6	0
175	Is there value in kinetic modeling of thrombin generation? Yes. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1463-1469.	1.9	36
176	Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1841-1848.	1.9	164
177	Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1830-1840.	1.9	89
178	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. <i>Lancet Neurology</i> , The, 2012, 11, 1066-1081.	4.9	75
180	New direct oral anticoagulants – current therapeutic options and treatment recommendations for bleeding complications. <i>Thrombosis and Haemostasis</i> , 2012, 108, 625-632.	1.8	64

#	ARTICLE	IF	CITATIONS
181	Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , 2012, 159, 427-429.	1.2	148
182	The promise of novel direct oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 351-360.	0.7	22
183	Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2012, 108, 217-224.	1.8	529
184	Vitamin K antagonists. <i>Hamostaseologie</i> , 2012, 32, 249-257.	0.9	8
185	Perioperative management of patients on chronic antithrombotic therapy. <i>Blood</i> , 2012, 120, 4699-4705.	0.6	72
186	Measurement of the new anticoagulants. <i>Thrombosis Research</i> , 2012, 129, S106-S113.	0.8	19
187	Dabigatran and thrombolysis: A therapeutic dilemma. <i>Annals of Neurology</i> , 2012, 72, 625-625.	2.8	0
189	Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2012, 35, 277-284.	0.6	52
190	Intravenous Thrombolysis in a Stroke Patient Taking Dabigatran. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 916.e11-916.e12.	0.7	34
191	Controversies in Neurosciences Critical Care. <i>Anesthesiology Clinics</i> , 2012, 30, 369-383.	0.6	3
193	Quoi de neuf sur les nouveaux anticoagulants oraux directs? <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2012, 2012, 24-27.	0.0	0
196	The Management of Anticoagulants Perioperatively. <i>Thoracic Surgery Clinics</i> , 2012, 22, 29-34.	0.4	4
197	Apixaban: A novel oral inhibitor of factor Xa. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1113-1126.	0.5	30
198	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	0.7	2,319
199	Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1101-1111.	0.9	9
200	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. <i>Pi<sup>1</sup> luci che ombre. Italian Journal of Medicine</i> , 2012, 6, 153-169.	0.2	0
201	Current anticoagulant safety. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 401-413.	1.0	5
202	Dabigatran-Induced Gastrointestinal Bleeding in an Elderly Patient with Moderate Renal Impairment. <i>Annals of Pharmacotherapy</i> , 2012, 46, 608-608.	0.9	97

#	ARTICLE	IF	CITATIONS
203	How I treat anticoagulated patients undergoing an elective procedure or surgery. <i>Blood</i> , 2012, 120, 2954-2962.	0.6	331
205	Dabigatran Etxilate: Clinical Implications in Dermatologic Surgery. <i>Dermatologic Surgery</i> , 2012, 38, 675-676.	0.4	2
206	Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention. <i>Thrombosis and Haemostasis</i> , 2012, 108, 579-581.	1.8	10
207	The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: Mechanistic implications for clinical medicine. <i>Thrombosis and Haemostasis</i> , 2012, 108, 586-588.	1.8	27
208	Impact of dabigatran on a large panel of routine or specific coagulation assays. <i>Thrombosis and Haemostasis</i> , 2012, 107, 985-997.	1.8	321
209	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012, 119, 2172-2174.	0.6	219
210	Hemorrhagic complications associated with dabigatran use. <i>Clinical Toxicology</i> , 2012, 50, 854-857.	0.8	46
211	How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. <i>Blood</i> , 2012, 119, 3016-3023.	0.6	226
212	Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran. <i>American Journal of Medicine</i> , 2012, 125, 417-420.	0.6	73
213	Clinical Challenges in a Patient With Dabigatran-Induced Fatal Hemorrhage. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 160-163.	3.0	67
214	Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 165-173.	0.7	12
216	Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. <i>Heart Lung and Circulation</i> , 2012, 21, 53-55.	0.2	25
217	Anti-stroke prophylaxis – the ethics of collateral damage. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 792-794.	0.8	8
219	Optimizing Drug Therapy in the Surgical Intensive Care Unit. <i>Surgical Clinics of North America</i> , 2012, 92, 1573-1620.	0.5	2
220	Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 734-740.	1.1	15
221	Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays. <i>American Journal of Clinical Pathology</i> , 2012, 138, 551-558.	0.4	69
222	Dabigatran Etxilate. <i>Drugs</i> , 2012, 72, 963-986.	4.9	23
223	New Oral Anticoagulants. <i>Drugs</i> , 2012, 72, 1739-1753.	4.9	76

#	ARTICLE	IF	CITATIONS
224	Management of Bleeding in Patients Receiving Conventional or New Anticoagulants. <i>Drugs</i> , 2012, 72, 1965-1975.	4.9	11
225	Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1627-1636.	0.9	99
226	Anticoagulants in atrial fibrillation patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 569-578.	4.1	72
227	Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etxilate Therapy. <i>American Journal of Clinical Pathology</i> , 2012, 137, 572-574.	0.4	83
228	Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1168-1174.	1.2	300
229	New Oral Anticoagulants: Good but Not Good Enough!. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1434.	1.2	0
232	Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. <i>American Journal of Emergency Medicine</i> , 2012, 30, 2082.e1-2082.e2.	0.7	20
233	New oral anticoagulants in the ED setting: a review. <i>American Journal of Emergency Medicine</i> , 2012, 30, 2046-2054.	0.7	19
234	Coagulation management in patients undergoing mechanical circulatory support. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2012, 26, 179-198.	1.7	77
235	Dabigatran in Clinical Practice. <i>Clinical Therapeutics</i> , 2012, 34, 2051-2060.	1.1	14
236	Clinical monitoring of the antithrombotic treatment. <i>Cor Et Vasa</i> , 2012, 54, e97-e103.	0.1	3
237	Practice Guidelines for Reversal of New and Old Anticoagulants. <i>Disease-a-Month</i> , 2012, 58, 448-461.	0.4	7
238	Assessment of Advantages and Disadvantages of Agents Used For Therapeutic Anticoagulation. <i>Disease-a-Month</i> , 2012, 58, 462-468.	0.4	0
239	The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters. <i>Thrombosis Research</i> , 2012, 130, 775-779.	0.8	22
240	Managing venous thromboembolism in Asia: Winds of change in the era of new oral anticoagulants. <i>Thrombosis Research</i> , 2012, 130, 291-301.	0.8	16
241	Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 113, 431-441.	0.2	70
242	Current strategies of anticoagulation therapy for patients with nonâ€œvalvular atrial fibrillation. <i>Journal of Arrhythmia</i> , 2012, 28, 324-329.	0.5	8
243	Laboratory tests and the new oral anticoagulants. <i>Thrombosis Research</i> , 2012, 130, S95-S97.	0.8	11

#	ARTICLE	IF	CITATIONS
245	Balancing Efficacy and Bleeding Risk in the Prevention of Stroke Due to Atrial Fibrillation with Newer Oral Anticoagulants. Indian Journal of Hematology and Blood Transfusion, 2012, 28, 129-143.	0.3	2
246	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	1.0	3,144
247	New Anticoagulants for Stroke Prophylaxis in Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2012, 12, 287-294.	1.0	8
248	A Reappraisal of Plasma, Prothrombin Complex Concentrates, and Recombinant Factor VIIa in Patient Blood Management. Critical Care Clinics, 2012, 28, 413-426.	1.0	10
249	Newer Anticoagulants in Critically Ill Patients. Critical Care Clinics, 2012, 28, 427-451.	1.0	7
250	Intracranial Hemorrhage. Emergency Medicine Clinics of North America, 2012, 30, 771-794.	0.5	214
251	Intracranial Hemorrhage: Diagnosis and Management. Neurologic Clinics, 2012, 30, 211-240.	0.8	35
252	No Influence of Dabigatran Anticoagulation on Hemorrhagic Transformation in an Experimental Model of Ischemic Stroke. PLoS ONE, 2012, 7, e40804.	1.1	33
253	Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thrombosis and Haemostasis, 2012, 107, 838-847.	1.8	201
254	Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?. Thrombosis, 2012, 2012, 1-9.	1.4	12
255	Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban. Thrombosis, 2012, 2012, 1-10.	1.4	12
256	Coagulation Measurement and Optimisation in Cardiac Surgery. , 0, , .		0
257	Highlights and hot topics from 2011 in Thrombosis and Haemostasis. Thrombosis and Haemostasis, 2012, 107, 196-199.	1.8	3
258	Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows. Italian Journal of Medicine, 0, , .	0.2	3
259	Surgery and invasive procedures in patients on long term treatment with oral direct thrombin or factor Xa inhibitors (update 2012). Sang Thrombose Vaisseaux, 2012, 24, 269-278.	0.1	2
260	Dabigatran: Will it Replace Warfarin for Stroke Prevention in Atrial Fibrillation?. Hospital Pharmacy, 2012, 47, 181-186.	0.4	0
261	Perioperative management of patients on chronic antithrombotic therapy. Hematology American Society of Hematology Education Program, 2012, 2012, 529-535.	0.9	19
262	26 Global- und Gruppentests. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
263	32 Monitoring der Antikoagulanzen. , 2012, , .		0
264	Should Direct Thrombin Inhibitors Replace Warfarin for Prophylaxis of Thromboembolism in Canadians with Atrial Fibrillation?. Canadian Journal of Hospital Pharmacy, 2012, 65, 401-5.	0.1	1
265	Dabigatran como posibilidad terapéutica en el síndrome de trombocitopenia inducida por heparina tipo II. Anales Del Sistema Sanitario De Navarra, 2012, 35, 521-524.	0.2	13
266	Monitoring new oral anticoagulants, managing thrombosis, or both?. Thrombosis and Haemostasis, 2012, 107, 803-805.	1.8	32
267	Will the new target-specific oral anticoagulants improve the treatment of venous thromboembolism?. Thrombosis and Haemostasis, 2012, 107, 1009-1011.	1.8	6
268	Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban. Thrombosis and Haemostasis, 2012, 108, 201-202.	1.8	13
269	Oral anticoagulation in chronic kidney disease: A huge challenge. Thrombosis and Haemostasis, 2012, 108, 3-5.	1.8	22
270	Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. Therapeutics and Clinical Risk Management, 2012, 8, 139.	0.9	6
271	Pro: “Antidote for new anticoagulants” Specific target of inhibition requires a specific target for neutralisation. Thrombosis and Haemostasis, 2012, 108, 621-622.	1.8	5
272	Direct thrombin inhibitors in cardiovascular disease. Nature Reviews Cardiology, 2012, 9, 402-414.	6.1	30
273	Oral Anticoagulant Therapy. Chest, 2012, 141, e44S-e88S.	0.4	1,323
274	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2012, 141, e531S-e575S.	0.4	891
275	New anticoagulant treatments to protect against stroke in atrial fibrillation. Heart, 2012, 98, 1341-1347.	1.2	39
276	Dabigatran etexilate: What do hospitalists need to know?. Journal of Hospital Medicine, 2012, 7, 262-269.	0.7	4
277	Hemopericardium in a Patient Treated with Dabigatran Etexilate. Pharmacotherapy, 2012, 32, e103-e107.	1.2	42
278	Implementing the new oral anticoagulants into the hospital formulary. American Journal of Hematology, 2012, 87, S127-32.	2.0	12
279	Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Annals of Neurology, 2012, 71, 624-633.	2.8	53
280	Emergency Management of Bleeding Associated With Old and New Oral Anticoagulants. Clinical Cardiology, 2012, 35, 730-737.	0.7	52

#	ARTICLE	IF	CITATIONS
281	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. <i>Circulation</i> , 2012, 126, 343-348.	1.6	494
282	Using Dabigatran in Patients With Stroke. <i>Stroke</i> , 2012, 43, 271-279.	1.0	38
285	Atrial fibrillation and heart failure in the elderly. <i>Heart Failure Reviews</i> , 2012, 17, 597-613.	1.7	38
286	Expression and Characterization of Recombinant Ecarin. <i>Protein Journal</i> , 2012, 31, 353-358.	0.7	9
287	First cascade Mitsunobu reactions for the synthesis of 2-benzoxazole-N-phenyl and 2-benzimidazole-N-phenyl derivatives. <i>Molecular Diversity</i> , 2012, 16, 157-162.	2.1	8
288	Effect of cellulose sulfate on the induction of hydrolysis of plasmin-specific chromogenic substrate and anticoagulant activity in rabbit blood plasma. <i>Pharmaceutical Chemistry Journal</i> , 2012, 46, 86-91.	0.3	0
289	Anticoagulation-Related Intracranial Hemorrhages. <i>Current Atherosclerosis Reports</i> , 2012, 14, 351-359.	2.0	17
290	Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban. <i>Advances in Therapy</i> , 2012, 29, 491-507.	1.3	29
291	Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 607-616.	0.8	23
292	Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 340-347.	1.0	15
293	Oral antithrombotic therapy and gastrointestinal bleeding: the good, the bad and the ugly. <i>International Journal of Clinical Practice</i> , 2012, 66, 2-4.	0.8	1
294	New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials. <i>Clinical Therapeutics</i> , 2012, 34, 894-901.	1.1	38
295	Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for the Management of Thromboembolic Disorders. <i>Clinical Therapeutics</i> , 2012, 34, 766-787.	1.1	18
296	Management of over anti-coagulation by transfusion. <i>ISBT Science Series</i> , 2012, 7, 47-50.	1.1	0
297	Acute Stroke Management in Patients Taking Dabigatran. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 616-622.	1.9	7
298	New oral anticoagulants: will they replace warfarin?. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 113, 575-580.	0.2	32
299	Novel antithrombotic agents for atrial fibrillation. , 2012, 134, 345-354.		3
302	Dabigatran, Product Familiarisation Programmes, who benefits, who shouldn't get it?. <i>Internal Medicine Journal</i> , 2012, 42, 113-116.	0.5	1



#	ARTICLE	IF	CITATIONS
303	Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 17-23.	2.0	8
304	Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment. <i>Neurocritical Care</i> , 2012, 16, 203-209.	1.2	32
305	Therapeutic Strategies in Acute Intracerebral Hemorrhage. <i>Neurotherapeutics</i> , 2012, 9, 87-98.	2.1	43
306	Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 22-27.	1.0	11
307	Oral anticoagulant-associated intracerebral hemorrhage. <i>Journal of Neurology</i> , 2012, 259, 212-224.	1.8	91
308	Diagnosis of Perioperative Coagulopathy—Plasma versus Whole Blood Testing. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, S9-S15.	0.6	23
310	Optimizing the Use of Anticoagulants (Heparins and Oral Anticoagulants) in the Elderly. <i>Drugs and Aging</i> , 2013, 30, 687-699.	1.3	17
311	Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4779-4784.	1.0	10
312	Acute Stroke Management in Patients With Known or Suspected Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2013, 29, S45-S53.	0.8	5
313	Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 37, 223-231.	0.6	33
314	A review of current agents for anticoagulation for the critical care practitioner. <i>Journal of Critical Care</i> , 2013, 28, 763-774.	1.0	3
315	New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation. <i>Neurologic Clinics</i> , 2013, 31, 659-675.	0.8	6
316	Perioperative management of anticoagulation in elective surgery. <i>ANZ Journal of Surgery</i> , 2013, 83, 814-820.	0.3	2
317	Oral anticoagulation during atrial fibrillation ablation: Facts and controversies. <i>Cor Et Vasa</i> , 2013, 55, e101-e106.	0.1	2
318	Disadvantages of VKA and requirements for novel anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 103-114.	0.7	43
319	New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 163-169.	0.7	9
320	Bleeding and antidotes in new oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 191-202.	0.7	84
321	A comparative study on the analytical performance of a charged aerosol detector and an ultraviolet detector for the RP-LC analysis of dabigatran etexilate in capsules. <i>Analytical Methods</i> , 2013, 5, 4777.	1.3	6

#	ARTICLE	IF	CITATIONS
322	Antiplatelet medications and evolving antithrombotic medication. <i>Skeletal Radiology</i> , 2013, 42, 753-764.	1.2	1
323	Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 384-393.	1.0	14
324	Target specific oral anticoagulants in the management of thromboembolic disease in the elderly. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 203-211.	1.0	3
325	Practical issues, limitations, and periprocedural management of the NOACs. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 212-222.	1.0	29
326	The future of inpatient anticoagulation management. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 375-386.	1.0	0
327	Monitoring target specific anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 387-390.	1.0	8
328	Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 140-146.	1.0	55
329	Dabigatran Excess: Case Report and Review of the Literature. <i>Cardiology and Therapy</i> , 2013, 2, 111-124.	1.1	8
330	Stroke Prevention in Atrial Fibrillation. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 98-104.	0.6	0
331	Bridging Therapy: A Challenging Area in the Management of Patients with Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 259-261.	1.0	3
332	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2013, 67, 516-526.	0.8	20
333	Treatment of Acute Stroke in Patients on Dabigatran: A Survey of US Stroke Specialists. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, 1312-1316.	0.7	24
334	Established and new-generation antithrombotic drugs in patients with cirrhosis – Possibilities and caveats. <i>Journal of Hepatology</i> , 2013, 59, 358-366.	1.8	107
335	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
336	Hemorrhagic Gastritis with Dabigatran in a Patient with Renal Insufficiency. <i>Journal of Emergency Medicine</i> , 2013, 44, e221-e225.	0.3	28
338	A systematic update on the state of novel anticoagulants and a primer on reversal and bridging. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2013, 1, 418-426.	0.9	7
339	Novel oral anticoagulants in acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 167, 2449-2455.	0.8	31
340	Novel thrombin and factor Xa inhibitors. <i>Current Opinion in Hematology</i> , 2013, 20, 552-557.	1.2	15

#	ARTICLE	IF	CITATIONS
341	Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S34-S44.	0.8	40
342	Periprocedural Management of Oral Anticoagulation in Patients With Atrial Fibrillation: Approach in the Era of New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S54-S59.	0.8	15
343	A specific antidote for dabigatran: functional and structural characterization. <i>Blood</i> , 2013, 121, 3554-3562.	0.6	541
344	New oral anticoagulants and regional anaesthesia. <i>British Journal of Anaesthesia</i> , 2013, 111, i96-i113.	1.5	72
345	Reversal of Novel Anticoagulants: Role of Clotting Factors and Complex Concentrates. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 200-207.	0.6	0
346	Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 208-216.	0.6	3
347	New Oral Anticoagulants in Non-Valvular Atrial Fibrillation. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 53-60.	1.0	3
348	Management of dabigatran-induced bleeding: expert statement. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 721-729.	1.0	14
349	Novel anticoagulants and laboratory testing. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 262-268.	0.7	44
350	Management of Intracerebral Hemorrhage in the Presence of Anticoagulant Therapy. <i>Topics in Stroke Rehabilitation</i> , 2013, 20, 131-138.	1.0	1
351	Measuring oral direct inhibitors of thrombin and factor-Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 756-760.	1.9	224
353	The Perioperative Medicine Consult Handbook. , 2013, , .		2
355	Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1259-1267.	0.6	6
356	Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) â€“ March 2013. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 382-393.	0.7	281
357	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1029-1049.	0.6	4
358	Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. <i>Drug Development Research</i> , 2013, 74, 485-491.	1.4	0
359	Management of bleeding and reversal strategies for oral anticoagulants: Clinical practice considerations. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1914-1929.	0.5	49
360	Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. <i>Critical Care</i> , 2013, 17, 230.	2.5	46

#	ARTICLE	IF	CITATIONS
361	Pharmacologic interventions for reversing the effects of oral anticoagulants. American Journal of Health-System Pharmacy, 2013, 70, S12-S21.	0.5	42
362	New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists. Clinical Pharmacokinetics, 2013, 52, 69-82.	1.6	172
363	Ineligibility for Anticoagulation in Patients with Atrial Fibrillation. American Journal of Medicine, 2013, 126, 105-111.	0.6	10
364	New Avenues for Anticoagulation in Atrial Fibrillation. Clinical Pharmacology and Therapeutics, 2013, 93, 68-77.	2.3	21
365	Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm, 2013, 10, 483-489.	0.3	139
366	Acute management of bleeding in patients on novel oral anticoagulants. European Heart Journal, 2013, 34, 489-498.	1.0	152
367	In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. Journal of Thrombosis and Thrombolysis, 2013, 35, 131-139.	1.0	15
368	Contemporary Anticoagulation Reversal. Journal of Pharmacy Practice, 2013, 26, 43-51.	0.5	6
369	The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology, 2013, 61, 772-782.	1.2	5
370	Influence des nouveaux anticoagulants sur les examens de la coagulation IntÃ©rÃ©t en clinique. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 21-27.	0.0	2
371	Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa). American Journal of Emergency Medicine, 2013, 31, 455.e3-455.e5.	0.7	13
372	Confronting the chronically anticoagulated, acute care surgery patient as we evolve into the post-warfarin era. Surgery, 2013, 153, 308-315.	1.0	2
373	â€œBlue letter effectsâ€: Changes in physiciansâ€™ attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan. Journal of Cardiology, 2013, 62, 366-373.	0.8	13
374	Managing Bleeding in Anticoagulated Patients in the Emergency Care Setting. Journal of Emergency Medicine, 2013, 45, 467-477.	0.3	21
375	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15, 625-651.	0.7	721
376	Gestion pÃ©ri-opÃ©ratoire des nouveaux anticoagulants oraux (NACOs). Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 7-12.	0.0	2
378	New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery. Journal of Clinical Neuroscience, 2013, 20, 1350-1356.	0.8	10
380	Dabigatran: A Primer for Neurosurgeons. World Neurosurgery, 2013, 79, 154-158.	0.7	7

#	ARTICLE	IF	CITATIONS
381	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012. Revista Espanola De Cardiologia, 2013, 66, 54.e1-54.e24.	0.6	14
382	Nuevos anticoagulantes orales y su papel en la pr3ctica cl3nica. Revista Espanola De Cardiologia Suplementos, 2013, 13, 33-41.	0.2	12
383	Dabigatran Etxilate Mesylate: Management Before Invasive Radiology Procedures. Journal of Radiology Nursing, 2013, 32, 66-69.	0.2	1
384	Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 116, e191-e195.	0.2	27
385	Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices. Thrombosis Research, 2013, 132, e161-e163.	0.8	19
386	Managing Blunt Trauma in Patients Receiving Dabigatran Etxilate: Case Study and Review of the Literature. Journal of Emergency Nursing, 2013, 39, 302-308.	0.5	4
387	What You See is Not Always What You Get: Raising the Bar on Clinical Trial Methodology in Ulcerative Colitis. Gastroenterology, 2013, 145, 45-47.	0.6	3
388	Thrombin inhibitors: surgical considerations and pharmacology. ANZ Journal of Surgery, 2013, 83, 215-221.	0.3	8
389	Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology, 2013, 160, 35-46.	1.2	197
390	Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring. British Journal of Clinical Pharmacology, 2013, 75, 569-570.	1.1	5
391	The Effect of Dabigatran on Select Specialty Coagulation Assays. American Journal of Clinical Pathology, 2013, 139, 102-109.	0.4	84
392	Effective elimination of dabigatran by haemodialysis. Thrombosis and Haemostasis, 2013, 109, 596-605.	1.8	184
393	Dabigatran Etxilate: Management In Acute Ischemic Stroke. American Journal of Critical Care, 2013, 22, 169-176.	0.8	9
394	The Laboratory and the New Oral Anticoagulants. Clinical Chemistry, 2013, 59, 353-362.	1.5	60
395	Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurology, The, 2013, 12, 394-405.	4.9	52
396	The novel anticoagulants: The surgeons' prospective. Surgery, 2013, 153, 303-307.	1.0	8
397	Measuring the anticoagulant effects of target specific oral anticoagulants3 reasons, methods and current limitations. Journal of Thrombosis and Thrombolysis, 2013, 36, 187-194.	1.0	53
398	Reversal of Oral Anticoagulation. Pharmacotherapy, 2013, 33, 1199-1213.	1.2	21

#	ARTICLE	IF	CITATIONS
399	Atrial fibrillation and stroke prevention: is warfarin still an option? Yes. <i>Journal of Neural Transmission</i> , 2013, 120, 1447-1451.	1.4	5
400	Dabigatran versus Warfarin Therapy for Uninterrupted Oral Anticoagulation During Atrial Fibrillation Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 861-865.	0.8	83
401	Improving the use of direct oral anticoagulants in atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013, 24, 288-294.	1.0	11
402	Reversal of novel oral anticoagulants in patients with major bleeding. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 391-398.	1.0	78
403	Moving Toward a More Ideal Anticoagulant. <i>Chest</i> , 2013, 143, 1106-1116.	0.4	28
404	Removal of Dabigatran by Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 487-489.	2.1	148
405	The role of anticoagulants, antiplatelet agents, and their reversal strategies in the management of intracerebral hemorrhage. <i>Neurosurgical Focus</i> , 2013, 34, E6.	1.0	28
406	Dabigatran, intracranial hemorrhage, and the neurosurgeon. <i>Neurosurgical Focus</i> , 2013, 34, E7.	1.0	14
407	The New Oral Anticoagulants in Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2013, 88, 495-511.	1.4	93
408	The Clinical Use of Prothrombin Complex Concentrate. <i>Journal of Emergency Medicine</i> , 2013, 44, 1201-1210.	0.3	37
409	Dabigatran: Is There a Role for Coagulation Assays in Guiding Therapy?. <i>Annals of Pharmacotherapy</i> , 2013, 47, 828-840.	0.9	8
410	Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors. <i>Annals of Pharmacotherapy</i> , 2013, 47, 841-855.	0.9	27
411	Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays. <i>Annals of Medicine</i> , 2013, 45, 423-429.	1.5	50
412	Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding: A Single Center Experience. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1533-1539.	2.2	91
413	Treatment of Bleeding Complications When Using Oral Anticoagulants for Prevention of Strokes. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2013, 15, 288-298.	0.4	24
414	Periprocedural Dabigatran in Atrial Fibrillation Ablation: A New Kid on the Block. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 866-868.	0.8	1
415	Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 37, 241-247.	0.6	38
416	Gastrointestinal disorders and dabigatran. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 9-16.	0.6	13

#	ARTICLE	IF	CITATIONS
417	Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. <i>Internal Medicine Journal</i> , 2013, 43, 778-783.	0.5	11
418	Atrial Fibrillation in the Elderly. <i>Drugs and Aging</i> , 2013, 30, 593-601.	1.3	29
419	Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1493-1502.	1.9	185
420	Novel Oral Anticoagulants: Is the Convenience Worth the Risk?. <i>Gastroenterology</i> , 2013, 145, 42-45.	0.6	4
421	Novel oral anticoagulants in gastroenterology practice. <i>Gastrointestinal Endoscopy</i> , 2013, 78, 227-239.	0.5	94
422	Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1875-1881.	0.8	98
423	The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. <i>Thrombosis and Haemostasis</i> , 2013, 110, 308-315.	1.8	78
424	Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 53-63.	1.0	6
425	The role of the laboratory in treatment with new oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 122-128.	1.9	69
426	Perioperative management of patients who are receiving a novel oral anticoagulant. <i>Internal and Emergency Medicine</i> , 2013, 8, 477-484.	1.0	46
427	Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban. <i>Canadian Journal of Cardiology</i> , 2013, 29, S24-S33.	0.8	162
428	Developing a management plan for oral anticoagulant reversal. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, S21-S31.	0.5	19
429	Oral bioavailability of dabigatran etexilate (<sup>P</sup>radaxa<sup>Â</sup>) after co-medication with verapamil in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1053-1062.	1.1	135
433	Oral anticoagulants in the management of venous thromboembolism. <i>Nature Reviews Cardiology</i> , 2013, 10, 397-409.	6.1	14
434	Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 37, 233-239.	0.6	30
435	Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. <i>Clinical Research in Cardiology</i> , 2013, 102, 399-412.	1.5	179
436	Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. <i>Lancet Neurology</i> , The, 2013, 12, 677-688.	4.9	80
437	5-Chlorothiophene-2-carboxylic Acid [( <i>S</i> )-2-[2-Methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a Selective and Potent Orally Active Dual Thrombin and Factor Xa Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9441-9456.	2.9	23

#	ARTICLE	IF	CITATIONS
438	Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery. <i>Journal of Cardiology Cases</i> , 2013, 8, e49-e50.	0.2	11
439	Acute Ischemic Stroke Following Cardioversion in a Patient Receiving Dabigatran. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1368-1371.	0.9	5
440	Management of New Anticoagulants in the ICU. <i>ICU Director</i> , 2013, 4, 326-331.	0.2	0
441	The Pharmacology and Therapeutic Use of Dabigatran Etxilate. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1-13.	1.0	22
442	Thrombolysis in a Stroke Patient on Dabigatran Anticoagulation: Case Report and Synopsis of Published Cases. <i>Case Reports in Neurology</i> , 2013, 5, 56-61.	0.3	16
443	Direct Thrombin and Factor Xa Inhibition for Stroke Prevention in Patients With Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 2013, 41, 26-36.	0.5	1
444	A New Era of Oral Anticoagulation in Atrial Fibrillation: Implications in Clinical Practice. <i>Hospital Practice (1995)</i> , 2013, 41, 61-70.	0.5	0
445	Inhibitory Effect of Apixaban Compared With Rivaroxaban and Dabigatran on Thrombin Generation Assay. <i>Hospital Practice (1995)</i> , 2013, 41, 19-25.	0.5	24
446	Drug use evaluation of dabigatran in a tertiary care hospital in United Arab Emirates. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, 106-109.	0.5	5
447	Dabigatran, ROCKET Atrial Fibrillation, and Beyond: Basic Science, Mechanisms of Agents, Monitoring, and Reversal. <i>Stroke</i> , 2013, 44, S38-S40.	1.0	6
448	Letter to the Editor: Anticoagulation. <i>Journal of Neurosurgery</i> , 2013, 118, 483-485.	0.9	2
452	Novel oral anticoagulants for the prevention and treatment of thromboembolism. <i>Future Cardiology</i> , 2013, 9, 849-861.	0.5	3
453	Novel Oral Anticoagulants: A Review of the Literature and Considerations in Special Clinical Situations. <i>Hospital Practice (1995)</i> , 2013, 41, 8-18.	0.5	3
454	Diagnosis and Management of Common Acquired Bleeding Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 172-181.	1.5	11
455	Problems and Solutions in Laboratory Testing for Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 816-833.	1.5	39
456	Intracerebral Bleeding in Patients on Antithrombotic Agents. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 963-971.	1.5	33
457	Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1635-1640.	0.9	41
458	New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: More Choices Bring More Challenges. <i>Hospital Pharmacy</i> , 2013, 48, 366-371.	0.4	2



#	ARTICLE	IF	CITATIONS
459	Development and Validation of a Stability-Indicating Liquid Chromatography Method for the Determination of Dabigatran Etxilate in Capsules. <i>Journal of AOAC INTERNATIONAL</i> , 2013, 96, 37-41.	0.7	17
460	New orally active anticoagulants in critical care and anesthesia practice: The good, the bad and the ugly. <i>Annals of Cardiac Anaesthesia</i> , 2013, 16, 193.	0.3	12
461	Anticoagulation in the Perioperative Period. , 2013, , 673-687.		1
462	Dabigatran bleed risk with closed head injuries: are we prepared?. <i>Journal of Neurosurgery</i> , 2013, 119, 760-765.	0.9	39
463	Main considerable factors for correct laboratory test interpretation under DOA treatment. <i>Thrombosis Journal</i> , 2013, 11, 22.	0.9	10
464	Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etxilate Use in a Patient with End-Stage Renal Disease. <i>Case Reports in Medicine</i> , 2013, 2013, 1-4.	0.3	14
465	Gastrointestinal amyloidosis associated with Schnitzler's syndrome. <i>Pathology</i> , 2013, 45, 424-426.	0.3	5
466	Management of Hemorrhage Complicated by Novel Oral Anticoagulants in the Emergency Department. <i>American Journal of Therapeutics</i> , 2013, 20, 300-306.	0.5	18
467	Treatment with novel oral anticoagulants. <i>Current Opinion in Hematology</i> , 2013, 20, 430-436.	1.2	27
468	Dabigatran: A Cause of Hematologic Emergency. <i>American Journal of the Medical Sciences</i> , 2013, 346, 190-193.	0.4	17
469	Re-excision perineural invasion in basal cell carcinoma. <i>Pathology</i> , 2013, 45, 433-435.	0.3	3
470	Novel anticoagulants. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 676-683.	1.0	34
471	II. On the reversal of new oral anti-coagulants: can we simply extrapolate data from the animal models to humans?. <i>British Journal of Anaesthesia</i> , 2013, 110, 329-332.	1.5	11
472	Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. <i>American Journal of Clinical Pathology</i> , 2013, 140, 610-622.	0.4	18
473	Immunohistochemistry in nodular fasciitis of the head and neck. <i>Pathology</i> , 2013, 45, 432-433.	0.3	10
474	Pituitary metastasis of an unknown neuroendocrine breast carcinoma mimicking a pituitary adenoma. <i>Pathology</i> , 2013, 45, 422-424.	0.3	8
475	Primary epithelial-myoepithelial carcinoma of lung: a case report of a rare salivary gland type tumour. <i>Pathology</i> , 2013, 45, 420-422.	0.3	11
476	An atypical presentation of persistent polyclonal B-lymphocytosis with symptomatic splenomegaly and response to rituximab. <i>Pathology</i> , 2013, 45, 437-440.	0.3	1

#	ARTICLE	IF	CITATIONS
477	Primary cutaneous vulvar extramammary Paget's disease involving the endocervix and detected by Pap smear. <i>Pathology</i> , 2013, 45, 426-428.	0.3	7
478	Primary hepatic inflammatory malignant fibrous histiocytoma: report of a rare entity and diagnostic pitfall mimicking a liver abscess. <i>Pathology</i> , 2013, 45, 430-432.	0.3	3
479	Delayed diagnosis of vaginal leiomyoma following misrepresentative core biopsy. <i>Pathology</i> , 2013, 45, 429-430.	0.3	0
480	Perioperative coagulation management in the intensive care unit. <i>Current Opinion in Anaesthesiology</i> , 2013, 26, 65-70.	0.9	11
481	New oral therapies for the prevention and treatment of venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 113-125.	0.5	7
482	Laboratory Monitoring of Anticoagulant Medications: Focus on Novel Oral Anticoagulants. <i>Postgraduate Medicine</i> , 2013, 125, 135-145.	0.9	6
483	Blood Component and Pharmacologic Therapy for Hemostatic Disorders. , 2013, , 496-525.		3
484	Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability between Coagulation Laboratories. <i>Clinical Chemistry</i> , 2013, 59, 807-814.	1.5	86
485	Therapeutic Apheresis. , 2013, , 546-562.		0
486	An Updated Review of Target-Specific Oral Anticoagulants Used in Stroke Prevention in Atrial Fibrillation, Venous Thromboembolic Disease, and Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2013, 2, e000136.	1.6	24
487	Novel Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation: Dawn of a New Era. <i>Postgraduate Medicine</i> , 2013, 125, 34-44.	0.9	11
488	Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 221-225.	0.7	4
489	Letter by May et al Regarding Article, "Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation" by Bassiouny et al.. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, e65.	2.1	2
490	Evaluation and Management of the Atrial Fibrillation Patient. <i>Critical Pathways in Cardiology</i> , 2013, 12, 107-115.	0.2	4
491	Laboratory testing for the new oral anticoagulants: a review of current practice. <i>Pathology</i> , 2013, 45, 435-437.	0.3	31
492	Treatment of Dabigatran-Associated Bleeding. <i>Journal of Pharmacy Practice</i> , 2013, 26, 264-269.	0.5	46
493	New oral anticoagulants and risks in ENT. <i>Clinical Otolaryngology</i> , 2013, 38, 355-357.	0.6	0
494	Pros and cons of new oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 464-470.	0.9	193

#	ARTICLE	IF	CITATIONS
495	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1203-1205.	1.9	6
496	<b>Utilization of Coagulation Assays in Clinical Therapeutics</b>. <i>Pharmacotherapy</i> , 2013, 33, 1214-1222.	1.2	5
497	Stroke thrombolysis in patients taking dabigatran. <i>Internal Medicine Journal</i> , 2013, 43, 826-828.	0.5	9
498	Intravenous Lipid Emulsion Does Not Reverse Dabigatran-Induced Anticoagulation in a Rat Model. <i>Academic Emergency Medicine</i> , 2013, 20, 1022-1025.	0.8	10
499	Response to Letter by May et al Regarding Article, "Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation" by Bassiouny et al. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, e66.	2.1	1
500	EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2013, 34, 2094-2106.	1.0	356
501	Dabigatran and Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1591-1597.	2.2	32
502	Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1461-1471.	0.6	2
503	Pejorative statement. <i>British Dental Journal</i> , 2013, 215, 104-104.	0.3	1
504	Bleeding sockets. <i>British Dental Journal</i> , 2013, 215, 104-104.	0.3	4
505	Anticoagulant update. <i>British Dental Journal</i> , 2013, 215, 103-104.	0.3	6
506	A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1105-1114.	0.6	7
507	Warfarin Replacements: Good for Patients, Challenging for Laboratories. <i>Clinical Chemistry</i> , 2013, 59, 732-734.	1.5	2
508	Current Approaches to Anticoagulation for Reducing Risk of Atrial Fibrillation-Related Stroke. <i>Journal of Pharmacy Practice</i> , 2013, 26, 204-213.	0.5	2
509	The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. <i>Expert Review of Hematology</i> , 2013, 6, 677-695.	1.0	36
510	Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2013, 110, 543-549.	1.8	92
511	Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. <i>Anesthesiology</i> , 2013, 118, 1466-1474.	1.3	158
512	Practical approaches to the treatment of atrial fibrillation: focus on stroke prevention using oral anticoagulant drugs. <i>Clinical Practice (London, England)</i> , 2013, 10, 317-332.	0.1	0

#	ARTICLE	IF	CITATIONS
513	Management of severe perioperative bleeding. <i>European Journal of Anaesthesiology</i> , 2013, 30, 270-382.	0.7	740
514	Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department. <i>Haematologica</i> , 2013, 98, e143-e144.	1.7	45
515	Diffuse bleeding after multiple trauma in a patient treated with Dabigatran. <i>European Journal of Anaesthesiology</i> , 2013, 30, 98-98.	0.7	0
516	Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity. <i>Critical Care Medicine</i> , 2013, 41, e42-e46.	0.4	92
517	Traumatic Intracranial Hemorrhage in Patients Taking Dabigatran. <i>Neurosurgery</i> , 2013, 73, E368-E374.	0.6	33
518	Is There a Shortage of Neurosurgeons in the United States?. <i>Neurosurgery</i> , 2013, 73, 354-366.	0.6	41
519	Dabigatran monitoring made simple?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 393-395.	1.8	9
520	The perioperative management of new direct oral anticoagulants: a question without answers. <i>Thrombosis and Haemostasis</i> , 2013, 110, 515-522.	1.8	76
521	Gastrointestinal bleeding with the new oral anticoagulants “defining the issues and the management strategies. <i>Thrombosis and Haemostasis</i> , 2013, 110, 205-212.	1.8	155
524	Monitoring of Heparins, Fondaparinux, Direct Thrombin Inhibitors and Oral Anti-Xa Medications. , 2013, , 933-937.		0
525	Prophylaxis for deep venous thrombosis and pulmonary embolism in surgery. , 0, , 234-251.		0
526	New Oral Anticoagulants in Atrial Fibrillation. , 2013, , .		0
527	Management of Bleeding Complications of Dabigatran. <i>Journal of Hematology &amp; Thromboembolic Diseases</i> , 2013, 02, .	0.1	1
528	Perioperative anticoagulation in device implantation: Benefitting the uninterrupted. <i>Thrombosis and Haemostasis</i> , 2013, 109, 3-4.	1.8	1
529	Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 223-232.	1.8	33
530	A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. <i>International Archive of Medicine</i> , 2013, 6, 46.	1.2	14
531	PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 551-556.	0.3	0
532	The practical management of bleedings during treatment with direct oral anticoagulants: the emergency reversal therapy. <i>Italian Journal of Medicine</i> , 2013, 7, 48.	0.2	2

#	ARTICLE	IF	CITATIONS
533	Alternative to oral dicoumarin anticoagulants: Considerations in dental care. <i>Journal of Clinical and Experimental Dentistry</i> , 2013, 5, e273-8.	0.5	17
534	Spinal Epidural Hematoma Following Epidural Steroid Injection in a Patient Treated with Dabigatran. <i>JBJS Case Connector</i> , 2013, 3, e64.	0.1	8
535	The Discovery of Dabigatran Etxilate. <i>Frontiers in Pharmacology</i> , 2013, 4, 12.	1.6	52
536	Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. <i>Thrombosis</i> , 2013, 2013, 1-10.	1.4	11
537	The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. <i>Vascular Health and Risk Management</i> , 2013, 9, 341.	1.0	16
538	Venous thromboembolism: Prophylactic and therapeutic practice guideline. <i>South African Medical Journal</i> , 2013, 103, 260.	0.2	28
539	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
541	Monitoring strategies for patients treated with the new oral anticoagulants and the need for laboratory evaluation of hemostasis. <i>Italian Journal of Medicine</i> , 2013, 7, 59.	0.2	0
542	Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 85.	1.3	4
543	New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. <i>Drug Design, Development and Therapy</i> , 2014, 8, 789.	2.0	90
544	Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. <i>PLoS ONE</i> , 2014, 9, e99276.	1.1	33
545	Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	35
547	A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using <i>Apc min/+</i> mice. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1121-1132.	1.8	6
548	Management of Severe Dabigatran-Related Hemorrhage: Case Report, Considerations for Management, and Recommendations. <i>Canadian Journal of Hospital Pharmacy</i> , 2014, 67, 43-7.	0.1	5
549	Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. <i>Thrombosis and Haemostasis</i> , 2014, 112, 79-86.	1.8	14
550	Dabigatran etexilate and traumatic brain injury: Evolving anticoagulants require evolving care plans. <i>World Journal of Clinical Cases</i> , 2014, 2, 362.	0.3	11
551	Immediate Treatment of the Anticoagulated Patient with Traumatic Intracranial Hemorrhage. , 2014, , .		0
552	Practical Management of Stroke Prevention in Patients with Atrial Fibrillation and Renal Impairment Receiving Newer Oral Anticoagulants: Focus on Rivaroxaban. <i>Journal of General Practice (Los Angeles)</i> , Tj ETQq1 1 0o784314 r9BT /Overlo		

#	ARTICLE	IF	CITATIONS
553	Direct oral anticoagulants and antiplatelet agents. <i>Hamostaseologie</i> , 2014, 34, 78-84.	0.9	16
554	The target-specific oral anticoagulants: practical considerations. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 510-513.	0.9	7
555	Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: A Sonoclot in vitro study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 591-598.	0.6	10
556	Dabigatran: patient management in specific clinical settings. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 503-508.	1.0	6
557	Hemostasis and Anticoagulants. , 2014, , 479-496.		3
559	Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. <i>Clinical Toxicology</i> , 2014, 52, 283-287.	0.8	17
560	Performance of Various Laboratory Assays in the Measurement of Dabigatran in Patients Receiving Therapeutic Doses. <i>American Journal of Clinical Pathology</i> , 2014, 141, 262-267.	0.4	33
561	Monitoring target-specific oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 329-333.	0.9	3
562	Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	23
563	Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	6
564	Fatal dabigatran-associated bleeding. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 358-359.	0.5	0
565	Race against the clock: Overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. <i>Journal of Neurosurgery</i> , 2014, 121, 1-20.	0.9	40
566	Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring?. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 756-765.	1.5	45
567	CardioPulse Articles. <i>European Heart Journal</i> , 2014, 35, 1825-1830.	1.0	3
568	The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. <i>Emergency Medicine Journal</i> , 2014, 31, 163-168.	0.4	64
571	Strategies for Urgent Reversal of Target-Specific Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2014, 42, 108-125.	0.5	0
572	Fatal dabigatran-associated bleeding. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 360-360.	0.5	1
573	Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Focus in the Geriatric Population. <i>The Consultant Pharmacist</i> , 2014, 29, 169-178.	0.4	5

#	ARTICLE	IF	CITATIONS
576	Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 628-636.	0.7	9
577	A proposal for dose adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 599-609.	1.1	25
579	Type A Aortic Dissection in a Patient on Dabigatran: Hemostasis Post Circulatory Arrest. <i>Annals of Thoracic Surgery</i> , 2014, 98, 2215-2216.	0.7	13
580	Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Clinical Cardiology</i> , 2014, 37, 32-47.	0.7	72
581	A modified prothrombin time to measure the anticoagulant activity of dabigatran. <i>Thrombosis Research</i> , 2014, 134, 1368-1369.	0.8	2
582	Advantages and limitations of the new anticoagulants. <i>Journal of Internal Medicine</i> , 2014, 275, 1-11.	2.7	69
583	Determination of dabigatran, rivaroxaban and apixaban by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1636-1646.	1.9	146
584	Management of Acute Stroke in Patients Taking Novel Oral Anticoagulants. <i>International Journal of Stroke</i> , 2014, 9, 627-632.	2.9	58
585	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. <i>Thrombosis Journal</i> , 2014, 12, 24.	0.9	45
586	Treatment options for venous thromboembolism: lessons learnt from clinical trials. <i>Thrombosis Journal</i> , 2014, 12, 27.	0.9	18
587	Management of Hemorrhage with the Target-Specific Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2014, 42, 75-83.	0.5	0
588	Dabigatran assessment in patients with acute complications using routine coagulation assays. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 426-434.	0.5	5
589	Applying "Patient Blood Management"™ in the trauma center. <i>Current Opinion in Anaesthesiology</i> , 2014, 27, 225-232.	0.9	23
590	"New"™ direct oral anticoagulants in the perioperative setting. <i>Current Opinion in Anaesthesiology</i> , 2014, 27, 409-419.	0.9	44
591	Emergent Reversal of Oral Anticoagulation. <i>AACN Advanced Critical Care</i> , 2014, 25, 5-12.	0.6	1
593	Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 597-605.	1.0	85
594	The newer direct oral anticoagulants: a practical guide. <i>Clinical Medicine</i> , 2014, 14, 165-175.	0.8	17
595	Targeting Therapy to the Fibrin-Mediated Pathophysiology of Acute Coronary Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 516-523.	0.7	4

#	ARTICLE	IF	CITATIONS
596	Emergency surgery and trauma in patients treated with the new oral anticoagulants. <i>Journal of Trauma and Acute Care Surgery</i> , 2014, 77, 486-494.	1.1	14
597	Target-Specific Oral Anticoagulants: Practice Issues for the Clinician. <i>Hospital Practice (1995)</i> , 2014, 42, 48-61.	0.5	1
598	Safety of new oral anticoagulant drugs: a perspective. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 8-20.	1.0	52
599	New oral anticoagulant agents â€“ general features and outcomes in subsets of patients. <i>Thrombosis and Haemostasis</i> , 2014, 111, 575-582.	1.8	58
600	Evaluation of Dabigatran Utilization and Risk Among Hospitalized Patients. <i>Annals of Pharmacotherapy</i> , 2014, 48, 349-353.	0.9	4
601	Novel Oral Anticoagulants in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 34-44.	1.0	23
602	Point-of-Care Coagulation Testing for Assessment of the Pharmacodynamic Anticoagulant Effect of Direct Oral Anticoagulant. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 624-631.	1.0	36
603	Direct Oral Anticoagulantsâ€™ Pharmacology, Drug Interactions, and Side Effects. <i>Seminars in Hematology</i> , 2014, 51, 89-97.	1.8	35
604	Perioperative Management Issues of Direct Oral Anticoagulants. <i>Seminars in Hematology</i> , 2014, 51, 112-120.	1.8	12
606	Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report. <i>Journal of Emergency Medicine</i> , 2014, 46, 525-529.	0.3	25
607	The Newer Anticoagulants in Thrombosis Control in Cancer Patients. <i>Seminars in Oncology</i> , 2014, 41, 339-345.	0.8	4
608	Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism: Evidence From Major Clinical Trials. <i>Seminars in Hematology</i> , 2014, 51, 121-130.	1.8	9
609	The pharmacology of novel oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 217-233.	1.0	54
610	Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 380-391.	1.0	42
611	Dabigatran-associated subdural hemorrhage: using thromboelastography (TEGÂ®) to guide decision-making. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 80-83.	1.0	27
612	Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 76-79.	1.0	13
613	Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series. <i>Journal of Medical Toxicology</i> , 2014, 10, 223-228.	0.8	23
615	Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. <i>Critical Care</i> , 2014, 18, R27.	2.5	89



#	ARTICLE	IF	CITATIONS
616	Portal Venous Thrombosis After Distal Pancreatectomy: Clinical Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 656-661.	0.9	8
617	Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 630-637.	0.7	19
618	The New Era of Anticoagulation. <i>Annals of Vascular Surgery</i> , 2014, 28, 503-514.	0.4	4
619	Novel Anticoagulants Should NOT Be Recommended for High-Risk Activity. <i>Wilderness and Environmental Medicine</i> , 2014, 25, 359-360.	0.4	2
620	Gestion pÃ©riopÃ©ratoire des nouveaux anticoagulants. <i>Praticien En Anesthesie Reanimation</i> , 2014, 18, 52-59.	0.0	0
621	New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 651-659.	0.7	25
622	Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies. <i>Thrombosis Research</i> , 2014, 133, 705-713.	0.8	37
623	Identification, Synthesis, and Strategy for the Reduction of Potential Impurities Observed in Dabigatran Etexilate Mesylate Processes. <i>Organic Process Research and Development</i> , 2014, 18, 744-750.	1.3	6
624	Perioperative management of patients on new oral anticoagulants. <i>British Journal of Surgery</i> , 2014, 101, 742-749.	0.1	74
625	Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants. <i>American Journal of Emergency Medicine</i> , 2014, 32, 375-382.	0.7	25
626	Toxin-induced Coagulopathy. <i>Emergency Medicine Clinics of North America</i> , 2014, 32, 53-78.	0.5	2
628	Novel Oral Anticoagulants: A Focused Review for Stroke Physicians. <i>International Journal of Stroke</i> , 2014, 9, 71-78.	2.9	12
631	Atrial Fibrillation Therapy. , 2014, , .		3
632	Novel Oral Anticoagulants for Stroke Prevention in the Geriatric Population. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 15-29.	1.0	4
633	Dabigatran-related coagulopathy: when can we assume the effect has â€œworn offâ€?. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1433-1434.	0.7	1
634	Cardioembolic stroke in a patient taking Dabigatran Etexilate: The first case report of clinical and pharmacologic resistance. <i>Journal of the Neurological Sciences</i> , 2014, 346, 348-349.	0.3	8
635	Protocol in managing oral surgical patients taking dabigatran. <i>Australian Dental Journal</i> , 2014, 59, 296-301.	0.6	52
636	Measurement of nonâ€œCoumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , 2014, 166, 830-841.	1.2	142

#	ARTICLE	IF	CITATIONS
637	Gestion pÃ©ri-opÃ©ratoire des nouveaux anticoagulants oraux. Journal Europeen Des Urgences Et De Reanimation, 2014, 26, 173-180.	0.1	0
638	New Oral Anticoagulants in the Management of Venous Thromboembolism: A Major Advance?. European Journal of Vascular and Endovascular Surgery, 2014, 48, 487-488.	0.8	2
639	Does dabigatran interfere with intraablation heparinization?. Thrombosis Research, 2014, 134, 742-743.	0.8	2
640	Management of anticoagulant-related intracranial hemorrhage: an evidence-based review. Critical Care, 2014, 18, 223.	2.5	13
641	Laboratory Monitoring of the Non-vitamin K Oral Anticoagulants. Journal of the American College of Cardiology, 2014, 64, 1140-1142.	1.2	25
642	Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. International Journal of Cardiology, 2014, 176, 794-799.	0.8	38
643	Secondary Prevention of Stroke in the Elderly: Focus on Drug Therapy. Drugs and Aging, 2014, 31, 721-730.	1.3	16
644	Laboratory Measurement of the Anticoagulant Activity of the Non-vitamin K Oral Anticoagulants. Journal of the American College of Cardiology, 2014, 64, 1128-1139.	1.2	414
645	Pathophysiology of Cardiopulmonary Bypass. Seminars in Cardiothoracic and Vascular Anesthesia, 2014, 18, 161-176.	0.4	51
647	Management of Anticoagulation Agents in Trauma Patients. Clinics in Laboratory Medicine, 2014, 34, 563-574.	0.7	20
648	Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays. Clinics in Laboratory Medicine, 2014, 34, 479-501.	0.7	29
649	Monitoring of Hematological and Hemostatic Parameters in Neurocritical Care Patients. Neurocritical Care, 2014, 21, 168-176.	1.2	10
650	Dabigatran Etxilate: A Review of Its Use in the Treatment of Acute Venous Thromboembolism and Prevention of Venous Thromboembolism Recurrence. Drugs, 2014, 74, 1785-1800.	4.9	23
651	What is the Role of Renal Replacement Therapy in the Setting of Dabigatran Toxicity?. Seminars in Dialysis, 2014, 27, 223-226.	0.7	2
653	Newer clinically available antithrombotics and their antidotes. Journal of Interventional Cardiac Electrophysiology, 2014, 40, 269-275.	0.6	9
654	Emergency Reversal of Anticoagulation: Novel Agents. Current Neurology and Neuroscience Reports, 2014, 14, 471.	2.0	13
655	Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?. Expert Opinion on Pharmacotherapy, 2014, 15, 1991-2001.	0.9	11
656	The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 326.	0.4	2

#	ARTICLE	IF	CITATIONS
658	New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations. American Journal of Cardiovascular Drugs, 2014, 14, 175-189.	1.0	71
659	Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thrombosis Journal, 2014, 12, 7.	0.9	14
660	The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thrombosis Journal, 2014, 12, 8.	0.9	47
661	On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. Thrombosis Research, 2014, 134, 783-789.	0.8	47
662	New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Internal Medicine Journal, 2014, 44, 525-536.	0.5	129
663	The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy. Current Therapeutic Research, 2014, 76, 76-83.	0.5	7
664	Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. Thrombosis Research, 2014, 134, 729-736.	0.8	28
665	An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. Journal of Clinical Pharmacology, 2014, 54, 901-909.	1.0	24
666	Proposed Approach to Thrombolysis in Dabigatran-Treated Patients Presenting with Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 1351-1355.	0.7	28
667	Common Questions in Anticoagulation Management in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2014, 6, 79-86.	0.7	1
668	An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system. American Journal of Emergency Medicine, 2014, 32, 1077-1084.	0.7	28
669	Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation. Journal of Arrhythmia, 2014, 30, 58-64.	0.5	8
670	The role of novel anticoagulants in the management of venous thromboembolism. Vascular Medicine, 2014, 19, 205-214.	0.8	8
671	Les nouveaux anticoagulants oraux directs : rôle du laboratoire d'automatisation. Revue Francophone Des Laboratoires, 2014, 2014, 37-51.	0.0	1
672	Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. British Journal of Clinical Pharmacology, 2014, 78, 630-638.	1.1	16
673	Acquired Bleeding Disorders. Emergency Medicine Clinics of North America, 2014, 32, 691-713.	0.5	9
674	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3341-3345.	1.0	9
675	Potential antidotes for reversal of old and new oral anticoagulants. Thrombosis Research, 2014, 133, S158-S166.	0.8	37

#	ARTICLE	IF	CITATIONS
676	Atrial fibrillation: Stroke prevention in focus. <i>Australian Critical Care</i> , 2014, 27, 92-98.	0.6	18
678	Management of Anticoagulants in the Perioperative Period for Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1713-1720.	2.3	3
679	Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 112, 419-420.	1.8	18
681	Management of intracranial hemorrhage: early expansion and second bleeds. , 0, , 257-273.		0
682	Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. <i>Blood</i> , 2014, 123, 1747-1756.	0.6	98
683	How I treat target-specific oral anticoagulant-associated bleeding. <i>Blood</i> , 2014, 123, 1152-1158.	0.6	108
684	An Approach to the Patient with Non-Surgical Bleeding and a Normal Coagulation Screen. <i>Proceedings of Singapore Healthcare</i> , 2014, 23, 21-27.	0.2	3
685	Non-vitamin K Antagonist Oral Anticoagulants (NOACs): a View from the Laboratory. <i>British Journal of Biomedical Science</i> , 2014, 71, 158-167.	1.2	13
687	The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. <i>Pathology</i> , 2015, 47, 355-364.	0.3	64
688	Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation. <i>Journal of Arrhythmia</i> , 2015, 31, 183-188.	0.5	11
690	Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 375-380.	1.0	8
691	New oral anticoagulants: an approach in older people. <i>Journal of Pharmacy Practice and Research</i> , 2015, 45, 217-225.	0.5	4
692	Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. <i>Clinical Cardiology</i> , 2015, 38, 684-691.	0.7	6
693	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	1.8	201
694	Influence of dabigatran and rivaroxaban on routine coagulation assays. <i>Thrombosis and Haemostasis</i> , 2015, 113, 154-164.	1.8	73
695	Dabigatran Etexilate. <i>Neurologist</i> , 2015, 20, 1-3.	0.4	2
696	Management of Bleeding Complications in Patients Taking Direct Oral Anticoagulants at a Large Tertiary Academic Medical Center. <i>Current Emergency and Hospital Medicine Reports</i> , 2015, 3, 162-167.	0.6	0
698	Design, Synthesis, and Biological Evaluation of Dabigatran Etexilate Mimics, a Novel Class of Thrombin Inhibitors. <i>Archiv Der Pharmazie</i> , 2015, 348, 595-605.	2.1	7

#	ARTICLE	IF	CITATIONS
699	Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 323-329.	1.2	37
700	Low-Dose Sip Feeding in Individuals with Malnutrition" Effects on the Nutritional Parameters. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2207-2208.	1.3	1
701	Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?. <i>Thrombosis Journal</i> , 2015, 13, 33.	0.9	6
702	The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban. <i>Critical Pathways in Cardiology</i> , 2015, 14, 53-61.	0.2	15
703	The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2087-2092.	1.9	32
704	A new generation of antiplatelet and anticoagulant medication and the implications for the dental surgeon. <i>Dental Update</i> , 2015, 42, 840-854.	0.1	9
705	Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage. <i>Anesthesiology</i> , 2015, 122, 387-398.	1.3	52
706	Insights into direct anticoagulants. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 492-498.	0.5	1
707	The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. <i>International Journal of Laboratory Hematology</i> , 2015, 37, e81-4.	0.7	25
708	Design, Synthesis, and Anti-Thrombotic Evaluation of Some Novel Fluorinated Thrombin Inhibitor Derivatives. <i>Archiv Der Pharmazie</i> , 2015, 348, 408-420.	2.1	9
709	Conservative Management of Intentional Massive Dabigatran Overdose. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2205-2207.	1.3	6
710	Generation of an anti-Dabigatran Monoclonal Antibody and Its Use in a Highly Sensitive and Specific Enzyme-Linked Immunosorbent Assay for Serum Dabigatran. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 594-599.	1.0	11
713	Non-Vitamin K Antagonist Oral Anticoagulants: The Clinician's New Challenge. <i>Journal of Osteopathic Medicine</i> , 2015, 115, 612-621.	0.4	3
714	Differential benefit risk assessment of DOACs in&nbsp;the treatment of venous thromboembolism: focus on dabigatran. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3557.	2.0	0
715	Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation. <i>Italian Journal of Medicine</i> , 2015, 9, 314.	0.2	0
716	Current and emerging strategies in the management of venous thromboembolism: benefit&nbsp;risk assessment of dabigatran. <i>Vascular Health and Risk Management</i> , 2015, 11, 271.	1.0	7
717	10 Venous Thromboembolism (DVT and PE): Diagnosis and Treatment. , 2015, , .		0
718	23 Risk of Anticoagulants and Antiplatelet Agents in Trauma Patients. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
719	Novel Oral Anticoagulation Laboratory Monitoring, Interaction and Treatment of Complications. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2015, 15, 115-119.	0.2	0
720	Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2015, 113, 77-84.	1.8	41
721	A Study of the Management of Patients Taking Novel Oral Antiplatelet or Direct Oral Anticoagulant Medication Undergoing Dental Surgery in a Rural Setting. <i>Dentistry Journal</i> , 2015, 3, 102-110.	0.9	5
722	CARDIAC SURGERY New oral anticoagulants – a practical guide. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2015, 2, 111-118.	0.1	22
723	New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 967.	0.9	308
724	Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2015, 15, 120-126.	0.2	1
726	Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	35
727	Estimation of dabigatran plasma concentrations in the perioperative setting. <i>Thrombosis and Haemostasis</i> , 2015, 113, 862-869.	1.8	53
728	Normalization of Activated Partial Thromboplastin Time Correlates with Low Levels of Dabigatran in a Patient with Severe Sepsis. <i>Case Reports in Critical Care</i> , 2015, 2015, 1-3.	0.2	0
729	Anticoagulation Drug Therapy: A Review. <i>Western Journal of Emergency Medicine</i> , 2015, 16, 11-17.	0.6	184
730	Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	22
731	Apixaban and oral implications. <i>Journal of Clinical and Experimental Dentistry</i> , 2015, 7, e528-e534.	0.5	4
732	Management of Direct Oral Anticoagulants in the Perioperative Setting. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 741-748.	0.6	11
733	Feasibility and Safety of Uninterrupted Dabigatran Therapy in Patients Undergoing Ablation for Atrial Fibrillation. <i>Internal Medicine</i> , 2015, 54, 1167-1173.	0.3	26
734	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. <i>Drugs</i> , 2015, 75, 979-998.	4.9	10
735	A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 113, 943-951.	1.8	231
736	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	1.8	132
737	Management of oral anticoagulation in the surgical patient. <i>ANZ Journal of Surgery</i> , 2015, 85, 620-625.	0.3	3

#	ARTICLE	IF	CITATIONS
738	Anticoagulation and Non-urgent Commercial Air Travel: A Review of the Literature. <i>Air Medical Journal</i> , 2015, 34, 269-277.	0.3	3
739	Emergency Reversal Strategies for Anticoagulation and Platelet Disorders. <i>Frontiers of Neurology and Neuroscience</i> , 2015, 37, 51-61.	3.0	1
740	NOACs and routine coagulation assays. How to interpret?. <i>International Journal of the Cardiovascular Academy</i> , 2015, 1, 41-42.	0.1	4
741	Management of Bleeding Associated with New Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 788-801.	1.5	17
742	Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1237-47.	1.4	20
743	Idarucizumab. <i>Circulation</i> , 2015, 132, 2412-2422.	1.6	141
744	Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Hospital Practice (1995)</i> , 2015, 43, 258-267.	0.5	3
745	Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. <i>Thrombosis Research</i> , 2015, 136, 693-696.	0.8	28
746	The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. <i>Indian Heart Journal</i> , 2015, 67, S13-S34.	0.2	11
747	Renal cell carcinoma to haemangioblastoma metastasis: A rare manifestation of Von Hippel-Lindau syndrome. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 215-218.	0.8	5
748	Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. <i>Odontology / the Society of the Nippon Dental University</i> , 2015, 103, 258-263.	0.9	20
749	Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. <i>Clinical Toxicology</i> , 2015, 53, 156-163.	0.8	29
750	Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men. <i>Xenobiotica</i> , 2015, 45, 663-671.	0.5	3
751	New oral anti-coagulants: Implications for neurosurgery. <i>British Journal of Neurosurgery</i> , 2015, 29, 182-188.	0.4	2
752	Dabigatran-Associated Intracranial Hemorrhage. <i>Neurohospitalist, The</i> , 2015, 5, 234-244.	0.3	12
753	Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism). <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2015, 64, 255-259.	0.1	2
754	The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from phase 3 clinical trials. <i>American Heart Journal</i> , 2015, 169, 315-322.	1.2	9
755	Does Dabigatran Increase the Risk of Delayed Hematoma Expansion in a Rat Model of Collagenase-induced Intracerebral Hemorrhage?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 374-380.	0.7	9

#	ARTICLE	IF	CITATIONS
756	Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?. Annual Review of Medicine, 2015, 66, 241-253.	5.0	19
757	Real-world variability in dabigatran levels in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis, 2015, 13, 353-359.	1.9	62
758	Recent Advances in the Development of Specific Antidotes for Target-Specific Oral Anticoagulants. Pharmacotherapy, 2015, 35, 198-207.	1.2	29
759	Novel oral anticoagulants: What dermatologists need to know. Journal of the American Academy of Dermatology, 2015, 72, 535-540.	0.6	27
760	Laboratory Assessment of the Anticoagulant Activity of Dabigatran. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 434-445.	0.7	13
761	Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. Journal of Thrombosis and Thrombolysis, 2015, 39, 395-402.	1.0	66
762	Farmacología cl�nica comparada de los anticoagulantes orales: AVK y nuevos anticoagulantes. EMC - Tratado De Medicina, 2015, 19, 1-5.	0.0	0
763	Management of dabigatran-induced bleeding with continuous venovenous hemodialysis. International Journal of Hematology, 2015, 101, 594-597.	0.7	10
764	Enhanced Elimination of Dabigatran Through Extracorporeal Methods. Journal of Medical Toxicology, 2015, 11, 85-95.	0.8	13
765	Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. Clinical Chemistry and Laboratory Medicine, 2015, 53, 185-97.	1.4	80
766	The Emergent Reversal of Coagulopathies Encountered in Neurosurgery and Neurology: A Technical Note. Clinical Medicine and Research, 2015, 13, 20-31.	0.4	6
767	Antiplatelet Therapy and Anticoagulation. , 2015, , 109-130.		0
768	Direct Oral Anticoagulants in Frail Older Adults: A Geriatric Perspective. Seminars in Thrombosis and Hemostasis, 2015, 41, 389-394.	1.5	23
769	New Oral Anticoagulants: How Do We Use Them Wisely?. Current Cardiology Reports, 2015, 17, 626.	1.3	1
770	Relation Between Dabigatran Concentration, as Assessed Using the Direct Thrombin Inhibitor Assay, and Activated Clotting Time/Activated Partial Thromboplastin Time in Patients With Atrial Fibrillation. American Journal of Cardiology, 2015, 115, 1696-1699.	0.7	13
771	From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. Thrombosis Research, 2015, 136, 154-160.	0.8	20
772	Treating pulmonary embolism in Pacific Asia with direct oral anticoagulants. Thrombosis Research, 2015, 136, 196-207.	0.8	5
773	Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal. Archives of Pathology and Laboratory Medicine, 2015, 139, 687-692.	1.2	34



#	ARTICLE	IF	CITATIONS
774	Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 177-194.	1.6	38
775	Laboratory Testing in the Era of Direct or Non-Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 208-227.	1.5	95
776	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	13.9	1,419
777	Assessing the anticoagulant effect of dabigatran in children: An in vitro study. <i>Thrombosis Research</i> , 2015, 135, 630-635.	0.8	29
778	Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. <i>Lancet, The</i> , 2015, 386, 680-690.	6.3	302
779	The New or Non-Vitamin K Antagonist Oral Anticoagulants: What Have We Learned Since Their Debut. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 188-194.	1.5	14
780	Pros and Cons of Vitamin K Antagonists and Non-Vitamin K Antagonist Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 178-187.	1.5	31
781	Quality and Safety Issues of Direct Oral Anticoagulants in the Emergency Department. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 348-354.	1.5	12
782	Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 665-673.	1.2	125
783	New oral anticoagulants in severe trauma patients: Enemy at the gates?. <i>Medicina Intensiva (English) Tj ETQq1</i> 1 0.784314 rgBT /Overlo 0,1	0.7	18
784	Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 122-138.	2.6	24
785	New Oral Anticoagulants. <i>Medical Clinics of North America</i> , 2015, 99, 759-780.	1.1	5
786	Dabigatran-Associated Spontaneous Acute Cervical Epidural Hematoma. <i>World Neurosurgery</i> , 2015, 83, 257-258.	0.7	18
787	Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis. <i>Thrombosis Research</i> , 2015, 135, 532-536.	0.8	11
788	New oral anticoagulants: a practical guide for physicians. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 134-145.	1.4	54
789	Nuevos anticoagulantes orales en el paciente traumatizado grave: ¿enemigo a las puertas?. <i>Medicina Intensiva</i> , 2015, 39, 167-171.	0.4	7
792	Management of Antiplatelet Agents and Anticoagulants in Patients with Gastrointestinal Bleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2015, 25, 449-462.	0.6	13
793	Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran. <i>International Journal of Emergency Medicine</i> , 2015, 8, 10.	0.6	7

#	ARTICLE	IF	CITATIONS
794	Global assays and the management of oral anticoagulation. <i>Thrombosis Journal</i> , 2015, 13, 9.	0.9	48
795	Measuring and Reversing the Effect of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs). <i>Circulation Journal</i> , 2015, 79, 289-291.	0.7	3
796	Monitoring of Anticoagulant Therapy. , 2015, , 135-171.		0
797	Management of anticoagulation in patients with acute gastrointestinal bleeding. <i>Digestive and Liver Disease</i> , 2015, 47, 621-627.	0.4	58
798	Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. <i>Thrombosis Research</i> , 2015, 136, 7-12.	0.8	142
799	Perioperative Management of Dabigatran. <i>Circulation</i> , 2015, 132, 167-173.	1.6	133
800	Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 235-242.	1.0	17
801	Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-4-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors. <i>Archiv Der Pharmazie</i> , 2015, 348, 353-365.	2.1	8
802	Development and validation of LC-MS/MS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 989, 37-45.	1.2	29
803	Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban. <i>Current Opinion in Critical Care</i> , 2015, 21, 127-133.	1.6	22
804	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1340-1360.	1.2	92
805	Dabigatran for the prevention and treatment of thromboembolic disorders. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 529-540.	0.6	6
806	Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 153, 493-503.	1.1	26
807	Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?. <i>Annals of Hematology</i> , 2015, 94, 1413-1414.	0.8	0
808	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1213-1223.	0.6	1
809	The evolving role of dabigatran etexilate in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2053-2072.	0.9	0
810	Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding. <i>British Journal of Haematology</i> , 2015, 168, 911-913.	1.2	0
811	Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L768-L775.	1.3	8

#	ARTICLE	IF	CITATIONS
812	Emergency Neurological Life Support: Pharmacotherapy. <i>Neurocritical Care</i> , 2015, 23, 48-68.	1.2	21
813	The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefitâ€“risk ratio. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 245-254.	1.5	9
814	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
815	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valveâ€“Induced Thrombin Generation. <i>Journal of the American Heart Association</i> , 2015, 4, e002322.	1.6	78
816	Characterization of Thrombin-Bound Dabigatran Effects on Protease-Activated Receptor-1 Expression and Signaling In Vitro. <i>Molecular Pharmacology</i> , 2015, 88, 95-105.	1.0	23
817	Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7405-7416.	1.4	6
818	Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 504.	2.0	7
819	CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. <i>Thrombosis Research</i> , 2015, 135, 62-67.	0.8	11
820	Intracerebral Hemorrhage in Patients Receiving Oral Anticoagulation Therapy. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 63-78.	1.3	8
822	Complications of Spinal Fluid Drainage in Thoracic and Thoracoabdominal Aortic Aneurysm Surgery in 724 Patients Treated From 1987 to 2013. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 342-350.	0.6	54
824	A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 462-472.	1.3	20
825	Monitoring of dabigatran therapy using Hemoclotâ„® Thrombin Inhibitor assay in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 95-100.	1.0	27
826	Outcome following intracranial hemorrhage associated with novel oral anticoagulants. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 212-215.	0.8	15
827	Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 427-433.	1.0	13
829	Pharmacology and mechanisms of action of new oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 10-20.	1.0	33
830	Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate. <i>Korean Circulation Journal</i> , 2016, 46, 99.	0.7	9
831	Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. <i>Thrombosis and Haemostasis</i> , 2016, 115, 562-569.	1.8	9
832	Dabigatran approaching the realm of heparin-induced thrombocytopenia. <i>Blood Research</i> , 2016, 51, 77.	0.5	8

#	ARTICLE	IF	CITATIONS
833	Dabigatran: A new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2016, 21, 0-0.	0.7	23
834	Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. <i>Emergency Medicine International</i> , 2016, 2016, 1-13.	0.3	22
835	Direct Oral Anticoagulants in Emergency Trauma Admissions. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2016, 113, 575-82.	0.6	35
836	Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1683.	2.0	9
837	Lupus-anticoagulant testing at NOAC trough levels. <i>Thrombosis and Haemostasis</i> , 2016, 116, 235-240.	1.8	47
838	New Direct Oral Anticoagulants (DOAC) and Their Use Today. <i>Dentistry Journal</i> , 2016, 4, 5.	0.9	36
839	Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population. <i>Dentistry Journal</i> , 2016, 4, 7.	0.9	3
840	Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. <i>Thrombosis and Haemostasis</i> , 2016, 116, 461-471.	1.8	29
841	Antiplatelets and Anticoagulants. , 2016, , 73-89.		0
842	A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 563-567.	0.5	2
843	Laboratory measurement of the direct oral anticoagulants. <i>British Journal of Haematology</i> , 2016, 172, 315-336.	1.2	79
844	Idarucizumab for Dabigatran Reversal Guideline. <i>Critical Pathways in Cardiology</i> , 2016, 15, 33-35.	0.2	2
845	Perioperative Management of Anticoagulationâ€™Review of Latest Evidence. <i>American Journal of Therapeutics</i> , 2016, 23, e474-e484.	0.5	8
846	Reversal of Target-Specific Oral Anticoagulants. , 2016, , 47-54.		0
847	Laboratory Monitoring. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 12-21.	1.0	19
848	Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysisâ€™A simulation analysis. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 597-608.	1.0	7
849	Carbonâ€™13 and carbonâ€™14 labeled dabigatran etexilate and tritium labeled dabigatran. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 648-656.	0.5	1
850	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016, 220, 417-428.	0.8	9

#	ARTICLE	IF	CITATIONS
851	Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. <i>Science Translational Medicine</i> , 2016, 8, 367ra168.	5.8	32
852	When to stop, how to reverse, and when to restart antithrombotic drugs periendoscopically in nonvariceal upper gastrointestinal bleeding. <i>Techniques in Gastrointestinal Endoscopy</i> , 2016, 18, 177-186.	0.3	0
854	Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators. <i>Pathology</i> , 2016, 48, 712-719.	0.3	17
855	Dosage plasmatique de quatre anticoagulants directs par UHPLC/DAD. <i>Toxicologie Analytique Et Clinique</i> , 2016, 28, 278-285.	0.1	0
856	Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. <i>International Journal of Cardiology</i> , 2016, 214, 292-298.	0.8	79
857	Dabigatran-related axillary hematoma and coagulopathy in a patient with a pacemaker: The lesson we learned from a case report. <i>European Geriatric Medicine</i> , 2016, 7, 47-49.	1.2	1
858	Diagnosis and Management of Coagulopathy-Related Intracerebral Hemorrhage. <i>Seminars in Neurology</i> , 2016, 36, 274-287.	0.5	1
859	Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests. <i>International Journal of Cardiology</i> , 2016, 208, 14-18.	0.8	31
860	Management of bleeding complications in patients with cancer on DOACs. <i>Thrombosis Research</i> , 2016, 140, S142-S147.	0.8	12
861	Overview of direct oral anticoagulant therapy reversal. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, s5-s13.	0.5	13
863	Design, synthesis, biological evaluation and molecular docking of novel substituted 1-ethyl-1H-benzimidazole fluorinated derivatives as thrombin inhibitors. <i>Journal of the Iranian Chemical Society</i> , 2016, 13, 1155-1166.	1.2	4
864	Management of novel oral anticoagulants in emergency and trauma surgery. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016, 14, 234-239.	0.8	5
865	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	2.5	40
866	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
867	Direct oral anticoagulant drug level testing in clinical practice: A single institution experience. <i>Thrombosis Research</i> , 2016, 143, 40-44.	0.8	46
868	Use of direct oral anticoagulants with regional anesthesia in orthopedic patients. <i>Journal of Clinical Anesthesia</i> , 2016, 32, 224-235.	0.7	14
869	The discovery of dabigatran etexilate for the treatment of venous thrombosis. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 717-731.	2.5	6
870	Evidence Supporting Idarucizumab for the Reversal of Dabigatran. <i>American Journal of Medicine</i> , 2016, 129, S73-S79.	0.6	12

#	ARTICLE	IF	CITATIONS
871	Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. American Journal of Medicine, 2016, 129, S89-S96.	0.6	12
872	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1170-1185.	0.8	243
874	Novel oral anticoagulants in non-valvular atrial fibrillation: Pharmacological properties, clinical trials, guideline recommendations, new antidote drugs and real-world data. International Journal of the Cardiovascular Academy, 2016, 2, 167-173.	0.1	4
875	Clinical practice guideline on thromboprophylaxis and management of anticoagulant and antiplatelet drugs in neurosurgical and neurocritical patients. Revista Española De Anestesiología Y Reanimación (English Edition), 2016, 63, 406-418.	0.1	0
876	Direct Oral Anticoagulants. Hematology/Oncology Clinics of North America, 2016, 30, 995-1006.	0.9	4
877	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Hematology/Oncology Clinics of North America, 2016, 30, 1019-1034.	0.9	9
878	New Oral Anticoagulants and Their Reversal Agents. Current Treatment Options in Neurology, 2016, 18, 47.	0.7	18
879	Evidence supporting idarucizumab for the reversal of dabigatran. American Journal of Emergency Medicine, 2016, 34, 33-38.	0.7	11
880	Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. American Journal of Emergency Medicine, 2016, 34, 46-51.	0.7	16
881	Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis. Pharmacotherapy, 2016, 36, e160-e165.	1.2	35
882	Measurement and prediction of dabigatran etexilate mesylate Form II solubility in mono-solvents and mixed solvents. Journal of Chemical Thermodynamics, 2016, 103, 44-50.	1.0	10
883	When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 623-627.	1.9	285
884	Hemodialysis for removal of dabigatran in a patient with gastric hemorrhage. Acute Medicine & Surgery, 2016, 3, 132-134.	0.5	3
886	Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus. British Journal of Anaesthesia, 2016, 117, 407-409.	1.5	15
887	Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation. Thrombosis Research, 2016, 145, 100-106.	0.8	7
888	Non-cytochrome P450-mediated bioactivation and its toxicological relevance. Drug Metabolism Reviews, 2016, 48, 473-501.	1.5	26
889	Coagulation Factors in the Interstitial Space. Protein Science Series, 2016, , 233-269.	0.0	0
890	Management of Bleeding Patients. , 2016, , .		3

#	ARTICLE	IF	CITATIONS
891	Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?. <i>International Journal of Stroke</i> , 2016, 11, 748-758.	2.9	46
892	Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. <i>Circulation</i> , 2016, 134, 248-261.	1.6	98
893	The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency. <i>Scientific Reports</i> , 2016, 6, 29242.	1.6	19
895	Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 670-676.	1.0	5
896	Total Thrombus Formation Analysis System (T <sub>TF</sub> AS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	39
897	Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. <i>BMC Oral Health</i> , 2016, 16, 5.	0.8	38
898	Use of Extracorporeal Techniques in the Removal of Dabigatran. <i>American Journal of Therapeutics</i> , 2016, 23, e485-e488.	0.5	0
899	An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. <i>Thrombosis Research</i> , 2016, 144, 158-164.	0.8	4
900	The Effect of Cardiopulmonary Bypass on Dabigatran Levels. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 1022-1026.	0.6	1
901	Drug Treatment of Venous Thromboembolism in the Elderly. <i>Drugs and Aging</i> , 2016, 33, 475-490.	1.3	6
902	Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. <i>Thrombosis Journal</i> , 2016, 14, 10.	0.9	11
903	An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 987-990.	1.9	17
904	Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6658-6670.	2.9	5
905	Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 293-300.	1.0	15
906	Letter to the Editor. <i>Journal of Intensive Care Medicine</i> , 2016, 31, 70-71.	1.3	0
907	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 15-31.	1.0	108
908	Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring. <i>Clinical Toxicology</i> , 2016, 54, 286-289.	0.8	8
909	Novel phenylalanine derived diamides as Factor XIa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 472-478.	1.0	26

#	ARTICLE	IF	CITATIONS
910	Stroke Related to Surgery and Other Procedures. , 2016, , 591-598.		0
911	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Annals of Hematology, 2016, 95, 437-449.	0.8	56
912	Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. Journal of Thrombosis and Haemostasis, 2016, 14, 89-97.	1.9	39
913	The laboratory's 2015 perspective on direct oral anticoagulant testing. Journal of Thrombosis and Haemostasis, 2016, 14, 886-893.	1.9	42
914	Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thrombosis Research, 2016, 139, 128-134.	0.8	33
915	Secondary Prevention of Cardioembolic Stroke. , 2016, , 1014-1029.e4.		0
916	Reversal agents for NOACs: Connecting the dots. Indian Heart Journal, 2016, 68, 559-563.	0.2	7
917	Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology, 2016, 55, 1726-1735.	0.9	29
918	Design, synthesis, biological evaluation and molecular docking studies of dabigatran analogs as potential thrombin inhibitors. Journal of the Iranian Chemical Society, 2016, 13, 347-357.	1.2	3
919	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. Thrombosis Research, 2016, 140, 81-88.	0.8	14
920	Novel oral anticoagulants in plastic surgery. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2016, 69, 585-593.	0.5	8
921	Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. TrAC - Trends in Analytical Chemistry, 2016, 84, 41-50.	5.8	17
922	Guía de práctica clínica sobre tromboprofilaxis y manejo de los fármacos anticoagulantes y antiagregantes en pacientes neuroquirúrgicos y neurocríticos. Revista Española De Anestesiología Y Reanimación, 2016, 63, 406-418.	0.1	2
923	Liquid Chromatographic Method Development for Forced Degradation Products of Dabigatran Etexilate: Characterisation and In Silico Toxicity Evaluation. Chromatographia, 2016, 79, 169-178.	0.7	6
924	New Target-Specific Oral Anticoagulants and Intracranial Bleeding: Management and Outcome in a Single-Center Case Series. World Neurosurgery, 2016, 88, 132-139.	0.7	16
925	Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation. Thrombosis Research, 2016, 138, 22-29.	0.8	20
926	Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 823-830.	0.6	11
927	An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. International Journal of Oral and Maxillofacial Surgery, 2016, 45, 618-630.	0.7	44



#	ARTICLE	IF	CITATIONS
928	Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 275-83.	1.4	35
929	Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations. <i>Annals of Clinical Biochemistry</i> , 2016, 53, 446-451.	0.8	25
930	The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs. <i>Perfusion (United Kingdom)</i> , 2016, 31, 424-430.	0.5	4
931	Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. <i>International Journal of Cardiology</i> , 2016, 202, 578-585.	0.8	34
932	Coagulation assessment with the new generation of oral anticoagulants. <i>Emergency Medicine Journal</i> , 2016, 33, 423-430.	0.4	58
933	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. <i>Europace</i> , 2016, 18, 955-964.	0.7	62
934	An Algorithmic Approach to Management of Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 511-517.	0.7	1
935	Practical Approach to VTE Management in Hospitalized Patients. <i>American Journal of Therapeutics</i> , 2017, 24, e442-e467.	0.5	2
936	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD <sup>2</sup> study. <i>Journal of Medical Economics</i> , 2017, 20, 435-442.	1.0	7
937	Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. <i>Thrombosis Research</i> , 2017, 152, 44-48.	0.8	46
939	Dabigatran ameliorates post-haemorrhagic hydrocephalus development after germinal matrix haemorrhage in neonatal rat pups. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3135-3149.	2.4	19
940	Reversing the anticoagulation effects of dabigatran. <i>Hospital Practice (1995)</i> , 2017, 45, 29-38.	0.5	13
941	Laboratory Assessment of Direct Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 277-290.	1.5	75
942	Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. <i>Drugs</i> , 2017, 77, 331-344.	4.9	19
943	Cutaneous Burn Injury Promotes Shifts in the Bacterial Microbiome in Autologous Donor Skin. <i>Shock</i> , 2017, 48, 441-448.	1.0	36
945	A sensitive label-free immunosensor for detection of Fetoprotein in whole blood based on anticoagulating magnetic nanoparticles. <i>Biosensors and Bioelectronics</i> , 2017, 95, 87-93.	5.3	50
946	Non-Hemodynamic Effects of Catecholamines. <i>Shock</i> , 2017, 48, 390-400.	1.0	58
947	Novel oral anticoagulants and exodontia: the evidence. <i>British Dental Journal</i> , 2017, 222, 623-628.	0.3	22

#	ARTICLE	IF	CITATIONS
948	Minocycline Prevents the Impairment of Hippocampal Long-Term Potentiation in the Septic Mouse. <i>Shock</i> , 2017, 48, 209-214.	1.0	29
949	Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit. <i>Shock</i> , 2017, 48, 436-440.	1.0	26
950	Protection by Inhaled Hydrogen Therapy in a Rat Model of Acute Lung Injury can be Tracked in vivo Using Molecular Imaging. <i>Shock</i> , 2017, 48, 467-476.	1.0	20
951	Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	64
952	The Reversal of Direct Oral Anticoagulants in Animal Models. <i>Shock</i> , 2017, 48, 144-158.	1.0	5
953	Novel electrochemical immune sensor based on Hep-PCA-PPy nanoparticles for detection of $\hat{\pm}$ -Fetoprotein in whole blood. <i>Analytica Chimica Acta</i> , 2017, 977, 36-43.	2.6	30
954	Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit. <i>Transfusion Medicine Reviews</i> , 2017, 31, 258-263.	0.9	5
955	Synthesis of potential impurities of dabigatran etexilate. <i>Synthetic Communications</i> , 2017, 47, 1225-1230.	1.1	1
956	Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. <i>International Journal of Hematology</i> , 2017, 105, 532-535.	0.7	7
957	In vitro and ex vivo Measurement of Prophylactic Dabigatran Concentrations with a New Ecarin-Based Thromboelastometry Test. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 100-105.	0.7	21
958	Anticoagulation and Neuraxial/Peripheral Anesthesia. <i>Anesthesiology Clinics</i> , 2017, 35, e21-e39.	0.6	5
959	Mechanisms Involved in Secondary Cardiac Dysfunction in Animal Models of Trauma and Hemorrhagic Shock. <i>Shock</i> , 2017, 48, 401-410.	1.0	18
960	Loss of Syndecan-1 Abrogates the Pulmonary Protective Phenotype Induced by Plasma After Hemorrhagic Shock. <i>Shock</i> , 2017, 48, 340-345.	1.0	42
961	Dabigatran in nonvalvular atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 467-477.	0.6	7
962	Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1036-1043.	0.8	52
963	Management of neurologic complications of coagulopathies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2017, 141, 743-764.	1.0	7
964	Anticoagulant Reversal and Anesthetic Considerations. <i>Anesthesiology Clinics</i> , 2017, 35, 191-205.	0.6	5
965	Bleeding Complications and Management on anticoagulant therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 886-892.	1.5	10

#	ARTICLE	IF	CITATIONS
966	Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 2002-2009.	1.4	7
967	Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 461-465.	0.5	7
968	Point-of-Care Coagulation Tests Monitoring of Direct Oral Anticoagulants and Their Reversal Therapy: State of the Art. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 423-432.	1.5	22
969	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	3.0	106
970	Reversal of direct oral anticoagulants. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2017, 78, 165-169.	0.2	1
971	Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 407-410.	1.2	11
972	Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. <i>Pharmacotherapy</i> , 2017, 37, 236-248.	1.2	97
973	Acquired Bleeding Disorders. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 1123-1145.	0.9	13
974	Idarucizumab since FDA approval: Use in the real-world. <i>American Heart Journal</i> , 2017, 193, 93-94.	1.2	6
975	Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice. <i>Thrombosis Research</i> , 2017, 159, 58-64.	0.8	27
976	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2377-2387.	1.9	19
977	Anticoagulation: The Successes and Pitfalls of Long-Term Management. <i>Physician Assistant Clinics</i> , 2017, 2, 603-622.	0.1	0
979	Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence. <i>CNS Drugs</i> , 2017, 31, 747-757.	2.7	37
980	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 527-535.	1.0	9
981	Hemorrhagic Transformation After Large Cerebral Infarction in Rats Pretreated With Dabigatran or Warfarin. <i>Stroke</i> , 2017, 48, 2865-2871.	1.0	5
982	ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives. <i>European Heart Journal Supplements</i> , 2017, 19, D70-D88.	0.0	6
983	In-vitro assessment of the effect of dabigatran on thrombosis of adult and neonatal plasma. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 551-557.	0.5	4
984	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	1.2	285

#	ARTICLE	IF	CITATIONS
987	Perforation digestive sous anticoagulant direct. Annales Francaises De Medecine D'Urgence, 2017, 7, 197-200.	0.0	0
988	Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 410-415.	0.7	47
989	Prognostic Value of Red Blood Cell Distribution Width on Bleeding Events in Nonvalvular Atrial Fibrillation Patients Taking Dabigatran (110 mg b.i.d.) after Catheter Ablation. Cardiology, 2017, 136, 215-221.	0.6	5
990	Impact of the Direct Oral Anticoagulants on Activated Clotting Time. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, e24-e27.	0.6	15
991	Practical Use of Thromboelastometry in the Management of Perioperative Coagulopathy and Bleeding. Transfusion Medicine Reviews, 2017, 31, 11-25.	0.9	36
992	Optimal Reversal of Novel Anticoagulants in Trauma. Critical Care Clinics, 2017, 33, 135-152.	1.0	10
993	Direct oral anticoagulant considerations in solid organ transplantation: A review. Clinical Transplantation, 2017, 31, e12873.	0.8	41
994	Surgery in the Thrombocytopenic and Coagulopathic Patient. , 2017, , 45-60.		0
995	To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. Journal of Thrombosis and Haemostasis, 2017, 15, 200-202.	1.9	1
996	Measurement and reversal of the direct oral anticoagulants. Blood Reviews, 2017, 31, 77-84.	2.8	133
997	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. Chest, 2017, 151, 127-138.	0.4	245
998	ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention. European Heart Journal Supplements, 2017, 19, D293-D308.	0.0	4
999	Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thrombosis and Haemostasis, 2017, 117, 269-276.	1.8	32
1000	Direct Oral Anticoagulant Drugs in Dental Clinical Practice. Acta Medica Martiniana, 2017, 17, 20-27.	0.4	0
1001	Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 202-215.	1.0	14
1002	Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. International Journal of Nephrology and Renovascular Disease, 2017, Volume 10, 135-143.	0.8	90
1003	Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World Journal of Gastroenterology, 2017, 23, 1954.	1.4	146
1004	Hemostasis in Intracranial Hemorrhage. Frontiers in Neurology, 2017, 8, 80.	1.1	25

#	ARTICLE	IF	CITATIONS
1005	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 457-467.	1.0	40
1006	Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran. <i>Journal of Clinical and Experimental Dentistry</i> , 2017, 9, 0-0.	0.5	11
1007	Direct oral anticoagulants: A retrospective study of bleeding, behavior, and documentation. <i>Oral Diseases</i> , 2018, 24, 243-248.	1.5	13
1008	Anticoagulation Reversal. , 2018, , 105-131.		0
1009	The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 442-447.	0.7	30
1010	Assessing an oral surgery specific protocol for patients on direct oral anticoagulants: a retrospective controlled cohort study. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2018, 47, 940-946.	0.7	27
1011	Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 12-15.	1.0	9
1012	Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 588-592.	1.0	4
1013	International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2018, 118, 437-450.	1.8	268
1014	Reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2018, 15, 273-281.	6.1	116
1015	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>British Journal of Anaesthesia</i> , 2018, 120, 645-656.	1.5	115
1016	The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG <sup>A</sup> ), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 25-30.	0.6	13
1017	Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients. <i>Clinical Cardiology</i> , 2018, 41, 646-651.	0.7	6
1018	Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization. <i>Thrombosis Research</i> , 2018, 167, 165-171.	0.8	11
1019	The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma. <i>Thrombosis Research</i> , 2018, 165, 38-43.	0.8	10
1020	Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy. <i>Regional Anesthesia and Pain Medicine</i> , 2018, 43, 263-309.	1.1	596
1021	Novel oral anticoagulants in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 201-208.	1.0	5
1022	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576

#	ARTICLE	IF	CITATIONS
1023	Dental implant surgery in patients in treatment by dabigatran. <i>Clinical Oral Implants Research</i> , 2018, 29, 644-648.	1.9	33
1024	Idarucizumab for dabigatran overdose in a child. <i>British Journal of Haematology</i> , 2018, 180, 457-459.	1.2	22
1025	Uninterrupted dabigatran for ablation in atrial fibrillation: Peering into the black box of intra-procedural anticoagulation. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2018, 37, 375.	0.6	0
1026	Perioperative Management of Antithrombotic Therapy in the Periprocedural Period of Patients Undergoing Hysterectomy. , 2018, , 299-305.		1
1027	Thrombin generation estimates the anticoagulation effect of direct oral anticoagulants with significant interindividual variability observed. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 148-154.	0.5	28
1028	Management of Oral Anticoagulant-associated Intracerebral Hemorrhage. <i>Journal of Stroke Medicine</i> , 2018, 1, 114-125.	0.2	0
1029	Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes. <i>Journal of Stroke</i> , 2018, 20, 292-301.	1.4	16
1030	Interventional Pain Procedures in Patients on Anticoagulants. , 2018, , 805-812.e2.		1
1031	Current and Emerging Technologies in Hematologic Testing. , 2018, , 65-88.		1
1032	First Report of Plant-Derived $\beta$ -Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model. <i>Journal of Natural Products</i> , 2018, 81, 2521-2530.	1.5	24
1033	Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. <i>Thrombosis Research</i> , 2018, 171, 62-67.	0.8	4
1034	Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 361-380.	1.0	17
1036	Testing and monitoring direct oral anticoagulants. <i>Blood</i> , 2018, 132, 2009-2015.	0.6	60
1037	Reversal of Systemic Anticoagulants and Antiplatelet Therapeutics. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 537-545.	0.8	11
1038	The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 117S-126S.	0.7	11
1039	In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etxilate. <i>Scientific Reports</i> , 2018, 8, 13290.	1.6	18
1040	Interruption and Reversal of Direct Oral Anticoagulants in Preprocedural and Acute Settings. <i>Journal of the American Board of Family Medicine</i> , 2018, 31, 817-827.	0.8	2
1041	Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects. <i>International Journal of Cardiology</i> , 2018, 271, 219-227.	0.8	19

#	ARTICLE	IF	CITATIONS
1042	Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on general measures. <i>International Journal of Cardiology</i> , 2018, 268, 80-84.	0.8	5
1043	Evaluating the analytical performance of four new coagulation assays for the measurement of fibrinogen, D-dimer and thrombin time. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 637-644.	0.7	8
1044	<scp>FDA</scp> Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals. <i>Pharmacotherapy</i> , 2018, 38, 967-980.	1.2	9
1045	Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. <i>International Journal of Hepatology</i> , 2018, 2018, 1-9.	0.4	66
1046	Idarucizumab: What Should We Know?. <i>Current Drug Targets</i> , 2018, 19, 81-88.	1.0	1
1047	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents. <i>Journal of Clinical Medicine</i> , 2018, 7, 29.	1.0	29
1048	Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation. <i>Thrombosis Journal</i> , 2018, 16, 3.	0.9	43
1049	Assessment of patients post reversal with idarucizumab. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 466-472.	1.0	10
1050	Research on biochar<i>via</i> a comprehensive scientometric approach. <i>RSC Advances</i> , 2018, 8, 28700-28709.	1.7	11
1051	Nucleophilic amination of methoxypyridines by a sodium hydride-iodide composite. <i>Chemical Communications</i> , 2018, 54, 10324-10327.	2.2	35
1052	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.4	718
1053	A study on indices of apixaban anticoagulation: A single-center prospective study. <i>Journal of Pharmacological Sciences</i> , 2018, 137, 105-109.	1.1	3
1054	Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists. <i>Hospital Practice (1995)</i> , 2019, 47, 113-122.	0.5	20
1056	Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 578-588.	1.0	19
1057	New Oral Anticoagulants: An Update. <i>Journal of Bangladesh College of Physicians &amp; Surgeons</i> , 2019, 37, 135-150.	0.0	0
1058	Emergency Reversal of Anticoagulation. <i>Western Journal of Emergency Medicine</i> , 2019, 20, 770-783.	0.6	46
1059	Clinical impact of direct oral anticoagulant measuring in a real-life setting. <i>Thrombosis Research</i> , 2019, 175, 40-45.	0.8	8
1060	Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 550-557.	1.0	14

#	ARTICLE	IF	CITATIONS
1061	Anticoagulation: a practical guide for strabismus surgeons. <i>Journal of AAPOS</i> , 2019, 23, 193-199.	0.2	4
1062	Impact of Total Antithrombotic Effect on Bleeding Complications in Patients Receiving Multiple Antithrombotic Agents. <i>Circulation Journal</i> , 2019, 83, 1309-1316.	0.7	4
1063	The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study. <i>PLoS ONE</i> , 2019, 14, e0217302.	1.1	15
1064	Patients on NOACs in the Emergency Room. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 40.	2.0	4
1065	Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy. <i>Journal of Anesthesia</i> , 2019, 33, 551-561.	0.7	4
1066	Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1354-1362.	1.9	28
1067	Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. <i>Europace</i> , 2019, 21, 879-885.	0.7	6
1068	Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature. <i>Clinical Neurology and Neurosurgery</i> , 2019, 181, 76-81.	0.6	8
1069	Postoperative bleeding associated with antiplatelet and anticoagulant drugs: A retrospective study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2019, 128, 243-249.	0.2	11
1070	Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983505.	0.7	5
1071	Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 230.	1.1	3
1072	Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 487-494.	1.0	14
1073	Initial management for acute lower gastrointestinal bleeding. <i>World Journal of Gastroenterology</i> , 2019, 25, 69-84.	1.4	44
1074	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Peri-procedural Management. <i>Critical Care Nurse</i> , 2019, 39, 54-67.	0.5	6
1075	Factor products. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 82-86.	0.5	0
1076	Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. <i>Future Medicinal Chemistry</i> , 2019, 11, 2595-2620.	1.1	20
1077	Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. <i>Hematologie</i> , 2019, 25, 233-247.	0.0	0
1078	Inducible Nitric Oxide Synthase (iNOS) Mediates Vascular Endothelial Cell Apoptosis in Grass Carp Reovirus (GCRV)-Induced Hemorrhage. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6335.	1.8	23



#	ARTICLE	IF	CITATIONS
1079	Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. <i>Annales De Biologie Clinique</i> , 2019, 77, 67-78.	0.2	1
1080	Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 180-191.	1.0	30
1081	Perioperative Dental Management of Patients in The Background of Antithrombotic Use. <i>Current Research in Dentistry</i> , 2019, 1, 30-39.	1.0	0
1082	Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 13-24.	1.1	68
1083	Assessment of direct oral anticoagulant assay use in clinical practice. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 403-408.	1.0	18
1084	The New Oral Anticoagulants and Anesthesia. , 2019, , 71-85.		0
1085	Performance of idarucizumab as antidote of dabigatran in daily clinical practice. <i>Europace</i> , 2019, 21, 414-420.	0.7	31
1086	Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. <i>Circulation</i> , 2019, 139, 748-756.	1.6	36
1087	Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 321-328.	0.8	6
1088	Effects of Direct Oral Anticoagulants on Quality of Life During Periprocedural Management for Dental Extractions. <i>Journal of Oral and Maxillofacial Surgery</i> , 2019, 77, 904-911.	0.5	6
1090	Laboratory Monitoring for Heparins, Fondaparinux, Direct Thrombin Inhibitors, and Oral Anti-Xa Medications. , 2019, , 933-938.		1
1091	Management of Bleeding Associated With Anticoagulation. , 2019, , 91-103.		0
1092	Hematologic Interventions for Acute Central Nervous System Disease. , 2019, , 778-801.		0
1093	Therapeutic Apheresis Applications for Hemorrhagic and Thrombotic Disorders. , 2019, , 573-593.		0
1094	Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 457-467.	1.0	6
1095	Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy. <i>Journal of Pharmacy Practice</i> , 2022, 35, 302-307.	0.5	2
1096	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	1.2	187
1097	The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etxilate: Meta-Analysis. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 699-705.	0.3	0

#	ARTICLE	IF	CITATIONS
1098	Anti-FXa-lla activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study. Cardiovascular Diagnosis and Therapy, 2020, 10, 1293-1302.	0.7	3
1099	Anticoagulants for Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1373-1382.	1.2	15
1100	Intra-procedural anticoagulation and post-procedural hemoglobin fall in atrial fibrillation ablation with minimally interrupted direct oral anticoagulants: comparisons across 4 drugs. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 551-557.	0.6	6
1101	Patients Taking Direct Oral Anticoagulants (DOAC) Undergoing Oral Surgery: A Review of the Literature and a Proposal of a Peri-Operative Management Protocol. Healthcare (Switzerland), 2020, 8, 281.	1.0	8
1102	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. Critical Pathways in Cardiology, 2020, 19, 178-186.	0.2	1
1103	Point-of-Care Hematology. , 2020, , 123-138.		0
1104	Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. Vascular Pharmacology, 2020, 130, 106679.	1.0	9
1105	Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature. Hamostaseologie, 2020, 40, 184-200.	0.9	21
1106	Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation. Blood Coagulation and Fibrinolysis, 2020, 31, 243-252.	0.5	2
1107	Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 151-156.	1.0	8
1108	Ecarin based coagulation testing. American Journal of Hematology, 2020, 95, 863-869.	2.0	19
1109	Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis. Clinical Toxicology, 2020, 58, 789-800.	0.8	7
1110	Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 569-581.	1.0	18
1111	An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants. Advances in Hematology, 2020, 2020, 1-10.	0.6	24
1112	Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 101-107.	0.3	0
1113	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Europace, 2021, 23, 65-72.	0.7	2
1114	The impact of <i>ABCB1</i> and <i>CES1</i> polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. British Journal of Clinical Pharmacology, 2021, 87, 2247-2255.	1.1	21
1115	Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery. Journal of Clinical Orthopaedics and Trauma, 2021, 12, 138-147.	0.6	7

#	ARTICLE	IF	CITATIONS
1116	Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently. <i>Circulation Research</i> , 2021, 128, 513-529.	2.0	26
1117	Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 058-069.	1.8	8
1118	Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery. , 2021, , 71-91.		0
1119	Pyridines and Their Benzo Derivatives: Applications. , 2022, , 217-242.		2
1120	Expert Consensus Decision Pathway of the American College of Cardiology on Management of Bleeding in Patients With Oral Anticoagulants: A Review of the 2020 Update for Perioperative Physicians. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 2471-2479.	0.6	5
1121	Updated recommendations for the treatment of venous thromboembolism. <i>Blood Research</i> , 2021, 56, 6-16.	0.5	11
1122	The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation. <i>Scientific Reports</i> , 2021, 11, 5920.	1.6	2
1123	Stroke due to Left Atrial Appendage Thrombus after Pulmonary Vein Isolation despite Novel Oral Anticoagulant: A Case Report. <i>Case Reports in Neurology</i> , 2021, 13, 225-232.	0.3	2
1124	Idarucizumab (Praxbind <sup>®</sup> ) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients. <i>Future Science OA</i> , 2021, 7, FSO689.	0.9	3
1125	COVID-19'ÜN DA ANTİKOAGÜLAN TEDAVİSİ. Sileyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 0, , 0.0	0.0	0
1126	Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life. <i>TH Open</i> , 2021, 05, e200-e210.	0.7	5
1127	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
1128	Applied Nanotechnologies in Anticoagulant Therapy: From Anticoagulants to Coagulation Test Performance of Drug Delivery Systems. <i>Applied Nano</i> , 2021, 2, 98-117.	0.9	2
1129	Direct oral anticoagulant reversal: An update. <i>Nursing</i> , 2021, 51, 54-64.	0.2	2
1130	The Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban: Results of the College of American Pathologists External Quality Assessment Program. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, , .	1.2	1
1131	Optimal interruption time of dabigatran oral administration to ablation (O-A time) in patients with atrial fibrillation: Integrated analysis of 2 randomized controlled clinical trials. <i>Journal of Cardiology</i> , 2021, 77, 652-659.	0.8	4
1132	Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2021, 71, 429-442.	0.2	2
1133	Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. <i>Clinical Therapeutics</i> , 2021, 43, e255-e263.	1.1	19

#	ARTICLE	IF	CITATIONS
1134	The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8531.	1.8	21
1135	Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production. <i>Cells</i> , 2021, 10, 2508.	1.8	4
1136	Stroke Related to Surgery and Other Procedures. , 2022, , 501-507.e4.		0
1137	Secondary Prevention of Cardioembolic Stroke. , 2022, , 932-943.e4.		0
1138	PHARMACODYNAMICS OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ACUTE PERIOD OF ISCHEMIC STROKE. <i>Farmatsiya I Farmakologiya</i> , 2021, 8, 222-232.	0.2	1
1139	Percutaneous Image-Guided Interventions Including Solid Organ Biopsies. , 2021, , 361-375.		0
1142	Hematologic Interventions for Acute Central Nervous System Disease. , 2013, , 737-753.		1
1143	Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2020, 42, 2066-2081.e9.	1.1	3
1144	The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. <i>Thrombosis Research</i> , 2018, 163, 190-195.	0.8	53
1145	Practical Emergency Resuscitation and Critical Care. , 2013, , .		2
1147	Haemostaseological complication management in caval and iliac venous stenting. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 243-246.	0.6	1
1148	Reversal of Dabigatran-induced Bleeding by Coagulation Factor Concentrates in a Rat-tail Bleeding Model and Lack of Effect on Assays of Coagulation. <i>Anesthesiology</i> , 2014, 120, 1429-1440.	1.3	50
1149	Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. <i>Anesthesiology</i> , 2020, 133, 223-232.	1.3	2
1150	Pain-associated Respiratory Failure in Chest Trauma. <i>Anesthesiology</i> , 2013, 118, 701-708.	1.3	19
1151	Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging "Real-World" Questions. <i>Thrombosis</i> , 2012, 2012, 1-10.	1.4	4
1152	The new oral anticoagulants and the future of haemostasis laboratory testing. <i>Biochemia Medica</i> , 2012, 22, 329-341.	1.2	45
1153	Perioperative management of patients on chronic antithrombotic therapy. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 529-35.	0.9	13
1154	Anticoagulants and the Propagation Phase of Thrombin Generation. <i>PLoS ONE</i> , 2011, 6, e27852.	1.1	24

#	ARTICLE	IF	CITATIONS
1155	Anticoagulation in Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2012, 1, 12.	1.3	2
1156	Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 04, 90.	1.3	2
1159	The Application of Different Groups of Medications for the Pharmacological Prevention of Thromboembolism After Major Orthopaedic Surgery in the Clinical Practice. <i>Flebologiya</i> , 2018, 12, 306.	0.2	3
1160	Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 789-798.	2.2	18
1161	Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. <i>Oncotarget</i> , 2018, 9, 5614-5626.	0.8	10
1162	Methods to monitor the therapy oral anticoagulants: the current problems.. <i>Klinicheskaia Meditsina</i> , 2018, 96, 101-105.	0.2	2
1163	DO WE KNOW ALL ABOUT PREVENTION OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPEDIC SURGERY?. <i>Travmatologiã I Ortopediã Rossii</i> , 2018, 24, 129-143.	0.1	9
1164	Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. <i>Blood Transfusion</i> , 2016, 14, 23-65.	0.3	78
1165	Dabigatran Etexilate : Pharmacology of the New, Oral Direct Thrombin Inhibitor. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2011, 22, 143-150.	0.1	1
1166	The 2018 Korean Heart Rhythm Society Practical Guidelines on the use of Non-Vitamin K-Antagonist Oral Anticoagulants: Bleeding Control and Perioperative Management. <i>Korean Journal of Medicine</i> , 2019, 94, 40-56.	0.1	7
1167	Dabigatran: Will it change clinical practice?. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 657-664.	0.6	10
1168	Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. <i>Cleveland Clinic Journal of Medicine</i> , 2013, 80, 443-451.	0.6	61
1169	When patients on target-specific oral anticoagulants need surgery. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 629-639.	0.6	8
1170	The new oral anticoagulants: Reasonable alternatives to warfarin. <i>Cleveland Clinic Journal of Medicine</i> , 2015, 82, 847-854.	0.6	22
1171	Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. <i>Journal of Thoracic Disease</i> , 2015, 7, 115-31.	0.6	8
1172	Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management. <i>Annals of Cardiac Anaesthesia</i> , 2015, 18, 517.	0.3	2
1173	Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update. <i>Indian Journal of Anaesthesia</i> , 2019, 63, 169.	0.3	17
1174	New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. <i>World Journal of Orthopedics</i> , 2014, 5, 188.	0.8	5

#	ARTICLE	IF	CITATIONS
1175	Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function. <i>Clinical Nephrology Case Studies</i> , 2014, 2014, 1-5.	0.3	2
1176	Pulmonary embolism hotline 2012. <i>Hamostaseologie</i> , 2013, 33, 43-50.	0.9	4
1177	Emergency abdominal Surgery in a patient anticoagulated With dabigatran. <i>Ulusal Travma Ve Acil Cerrahi Dergisi</i> , 2013, 19, 469-471.	0.1	1
1178	Recent Progress in Antithrombotic Therapy for Atrial Fibrillation. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 257-273.	0.9	3
1179	Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation. <i>Journal of Stroke</i> , 2013, 15, 144.	1.4	9
1180	Anticoagulation: Where have we come from and where are we going? The evidence for and against novel anticoagulants. <i>South African Medical Journal</i> , 2014, 104, 143.	0.2	1
1181	ニホントセキ Igaku Zasshi 2014, 114, 1-5.		
1182	Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management. <i>Polish Archives of Internal Medicine</i> , 2011, 121, 73-80.	0.3	5
1183	Enoxaparin and Dabigatran Thromboprophylaxis after Total Hip Arthroplasty. <i>N N Priorov Journal of Traumatology and Orthopedics</i> , 2011, 18, 67-70.	0.1	1
1184	Perioperative Management of Antithrombotic Therapy in Cardiovascular Patients. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 7, 10.	0.5	1
1187	Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation. <i>Research Reports in Clinical Cardiology</i> , 0, , 11.	0.2	0
1189	Prevention of thromboembolic complications of atrial fibrillation: Current aspects and perspective. <i>Srcce I Krvni Sudovi</i> , 2012, 31, 68-76.	0.1	1
1190	Inhibition of Thrombin as a Novel Strategy in the Treatment of Scleroderma-Associated Interstitial Lung Disease. , 0, , .		0
1191	Perioperative Management of Anticoagulation in the Patient with the Antiphospholipid Syndrome in Cardiac Surgery and Cardiac Interventions. , 2013, , 109-127.		0
1192	Management of Antiaggregated and Anticoagulated Patients Scheduled for Orthopedic Surgery. , 2013, , 153-165.		0
1194	Lowering the Risk for Thrombus and Stroke in Atrial Fibrillation Patients: Will Dabigatran Replace Warfarin?. <i>Clinical Medicine Reviews in Vascular Health</i> , 2013, 5, 1-8.	3.0	0
1195	The Proposal on Evaluating the Risk of Bleeding and Ischemia in the Therapy by Novel Oral Anticoagulants : Is it Possible?. <i>Japanese Journal of Electrocardiology</i> , 2013, 33, 49-58.	0.0	0
1196	Risk factors for Venous thromboembolism and duration of anticoagulation therapy. <i>Scripta Medica</i> , 2013, 44, 35-42.	0.0	0

#	ARTICLE	IF	CITATIONS
1197	Anticoagulation for Atrial Fibrillation and Prosthetic Cardiac Valves. , 2013, , 786-799.		0
1198	PHARMACOLOGICAL ASPECTS OF NEWER DRUGS USED IN ANTICOAGULANT THERAPY. Journal of Evolution of Medical and Dental Sciences, 2013, 2, 986-992.	0.1	0
1200	Assessment of Bleeding Risk of Interventional Techniques: A Best Evidence Synthesis of Practice Patterns and Perioperative Management of Anticoagulant and Antithrombotic Therapy. Pain Physician, 2013, 2s;16, SE216-SE318.	0.3	11
1201	Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. Polish Archives of Internal Medicine, 2013, 123, 623-634.	0.3	7
1202	Anticoagulation for Venous Thromboembolism. , 2014, , 293-307.		0
1203	Peri-device Implantation Anticoagulation Management: Evidence and Clinical Implications. , 2014, , 653-664.		0
1204	Detection and Management of Atrial Fibrillation in Patients with Stroke or TIA in Clinical Practice. , 2014, , 221-236.		0
1205	Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation. , 2014, , 55-89.		0
1206	Prolonged PTT. , 2014, , 57-70.		0
1207	Newer Oral Anticoagulants. , 2014, , 237-248.		0
1209	Haemostatic failure. , 2014, , 1003-1016.e3.		0
1211	Atrial Fibrillation and Heart Failure in the Aging Population. , 2014, , 65-84.		0
1212	Pharmacological characteristics of novel oral anticoagulant drugs for thromboprophylaxis in atrial fibrillation. Srce I Krvni Sudovi, 2014, 33, 179-186.	0.1	0
1213	Emergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies. AACN Advanced Critical Care, 2014, 25, 5-12.	0.6	0
1214	TEG ir naujieji peroraliniai antikoagulantai. Health Sciences, 2014, 24, 72-77.	0.0	0
1217	Anticoagulation Management in the Emergency Department. , 2015, , 229-248.		0
1218	Gestion pÃ©ri-opÃ©ratoire des patients traitÃ©s par antithrombotiques en chirurgie orale. Argumentaire. Medecine Buccale Chirurgie Buccale, 2015, 21, S15-S81.	0.1	1
1219	Neue orale Antikoagulanzen in der perioperativen Medizin. , 2015, , 107-122.		0

#	ARTICLE	IF	CITATIONS
1220	Management of bleeding with oral anticoagulants in patients with atrial fibrillation. <i>Hamostaseologie</i> , 2015, 35, 351-357.	0.9	1
1221	Oral surgery in patients under antithrombotic therapy. Narrative review.. <i>Journal of Oral Research</i> , 2015, 4, 58-64.	0.0	1
1222	Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician. <i>Acute Medicine</i> , 2015, 14, 83-89.	0.1	3
1225	Considerations for Coagulation in the Multi-trauma Patient. , 2016, , 257-267.		0
1227	The Evolution of the Management of Patients with Dabigatran Associated Hemorrhage. <i>Journal of Blood Disorders and Medicine</i> , 2016, 1, .	0.0	0
1228	Percutaneous Image-Guided Interventions Including Solid Organ Biopsies. , 2016, , 281-293.		0
1229	Comparison of plasma levels of soluble fibrin monomer complex in patients with acute ischemic stroke before and after commencement of antithrombotic treatment. <i>Nosotchu</i> , 2016, 38, 387-392.	0.0	0
1230	Anticoagulation in Cardiovascular Diseases. , 2016, , 195-214.		0
1231	Safe Strategies for Gradual Suspension and Reinstitution of Anticoagulation to Permit Elective Surgery. , 2016, , 297-307.		0
1232	Oral Anticoagulants. , 2016, , 1-16.		0
1233	Implications of apixaban for dental treatments. <i>Journal of Clinical and Experimental Dentistry</i> , 2016, 8, 0-0.	0.5	6
1234	Management of Chronically Anticoagulated Patients. , 2016, , 529-542.		0
1235	Amidoximes and their masked derivatives as prodrugs of amidines – arginine mimetics. <i>Journal of Organic and Pharmaceutical Chemistry</i> , 2016, 14, 36-45.	0.0	0
1236	Applying the Principles of Bridging Therapy at Concomitant Acute Hepatic Failure. <i>Emergency Medicine</i> , 2016, .	0.0	1
1238	Dabigatran - clinical evidence for treatment in patients with thromboembolism. <i>Klinicka Farmakologie A Farmacie</i> , 2016, 30, 15-17.	0.1	1
1239	Overview of the Direct Oral Anticoagulants. <i>Journal of the Minneapolis Heart Institute Foundation</i> , 2017, 1, 38-58.	0.0	1
1240	Oral Anticoagulants. , 2017, , 1325-1339.		0
1241	A Systematic Review of the Hemorrhage Risk for Patients on Antithrombotic Medication after Dental Procedures. <i>World Journal of Dentistry</i> , 2018, 9, 59-67.	0.1	0



#	ARTICLE	IF	CITATIONS
1242	ACTIVATED PARTIAL THROMBOPLASTIN TIME AS INDICATOR OF DABIGATRAN EFFICIENCY IN PATIENTS WITH NON - VALVULAR ATRIAL FIBRILLATION. Acta Medica Medianae, 2018, 57, 135-140.	0.0	1
1243	Oral anticoagulants: Optimizing venous thromboembolism management. Journal of Applied Hematology, 2019, 10, 111.	0.1	0
1244	A Systematic Review of Hemorrhage Risk in Patients on the New Oral Anticoagulant Therapy Postdental Implant Placement. World Journal of Dentistry, 2019, 10, 154-157.	0.1	2
1245	Extremely Elevated International Normalized Ratio in a Patient with Dabigatran Etexilate Use. Cureus, 2019, 11, e4906.	0.2	1
1246	Coagulation Management in Neurosurgical Critical Care. , 2020, , 593-599.		0
1247	Manejo das Hemorragias Relacionadas aos Anticoagulantes Oraais de Ação Direta. Journal of Cardiac Arrhythmias, 2019, 32, 89-96.	0.1	0
1248	Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication. Journal of Cardiac Arrhythmias, 2019, 32, 89-96.	0.1	0
1249	Thromboseneigung. Springer Reference Medizin, 2020, , 1-9.	0.0	0
1250	Bleeding on Anti-Xa Drugs: "Does All Bleeding Really Stop?", 2020, , 1-17.		0
1251	Amidoxime-Functionalized (9,10-Dioxoantracen-1-yl)hydrazones. Chemistry and Chemical Technology, 2019, 13, 417-423.	0.2	0
1253	Prolonged Coagulopathy With Dabigatran Despite Multiple Doses of Idarucizumab. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	1
1254	High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood. Anesthesia and Analgesia, 2021, 132, 566-574.	1.1	7
1255	The prevention and treatment of bleeding associated with direct oral anticoagulants. Klinicheskaia Meditsina, 2020, 96, 491-497.	0.2	0
1256	Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects. Meditsinskiy Sovet, 2020, , 65-73.	0.1	0
1257	Thromboseneigung. Springer Reference Medizin, 2020, , 37-45.	0.0	0
1258	Coagulation test and anti-factor Xa activity in patients treated with edoxaban. Nosotchu, 2020, 42, 80-83.	0.0	0
1259	Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. Journal of Thrombosis and Haemostasis, 2022, 20, 92-103.	1.9	19
1261	Direct oral anticoagulant reversal. Nurs Crit Care (Amblar), 2020, 15, 18-29.	0.3	1

#	ARTICLE	IF	CITATIONS
1262	Dabigatran versus Warfarin for the Treatment of Pediatric Thromboembolism: A Pilot Randomized Trial. <i>Pharmaceutical Sciences</i> , 2020, 26, 338-342.	0.1	1
1263	Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 11-21.	0.8	6
1264	Improving anticoagulation management in patients with atrial fibrillation. <i>P and T</i> , 2013, 38, 173-7.	1.0	0
1265	Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety. <i>Ochsner Journal</i> , 2013, 13, 419-27.	0.5	8
1266	Atrial fibrillation anticoagulation care in a large urban family medicine practice. <i>Canadian Family Physician</i> , 2014, 60, e173-9.	0.1	6
1267	New oral anticoagulants for atrial fibrillation: are they worth the risk?. <i>P and T</i> , 2014, 39, 54-64.	1.0	10
1268	Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty. <i>American Health and Drug Benefits</i> , 2012, 5, 115-22.	0.5	3
1269	Is intravenous recombinant tissue plasminogen activator (r-tPA) safe in patients on Dabigatran?. <i>Journal of Vascular and Interventional Neurology</i> , 2014, 7, 21-2.	1.1	1
1270	Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 224-31.	0.7	11
1271	Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillation. <i>American Journal of Cardiovascular Disease</i> , 2014, 4, 70-8.	0.5	7
1272	Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. <i>Canadian Family Physician</i> , 2014, 60, 997-1001.	0.1	10
1273	Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. <i>P and T</i> , 2014, 39, 858-80.	1.0	6
1274	Is dabigatran efficacy enough to prevent stroke in atrial fibrillation patient with high CHADS2 score during peri-procedural catheter radiofrequency ablation? A case report with literature review. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 6592-600.	1.3	1
1275	Coagulation Testing For New Oral Anticoagulants. <i>Journal of Atrial Fibrillation</i> , 2015, 8, 1089.	0.5	4
1276	Advances in Oral Coagulants. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2013, 23, 150-3.	0.7	0
1277	New Stroke Prophylaxis Options in Atrial Fibrillation Patients. <i>Journal of Atrial Fibrillation</i> , 2013, 5, 462.	0.5	0
1278	Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis. <i>P and T</i> , 2017, 42, 692-698.	1.0	6
1279	Dabigatran: a new anticoagulant for stroke prevention in patients with atrial fibrillation. <i>Missouri Medicine</i> , 2012, 109, 146-9.	0.3	0

#	ARTICLE	IF	CITATIONS
1280	Use of direct oral anticoagulants in daily practice. American Journal of Blood Research, 2018, 8, 57-72.	0.6	18
1281	Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors. Journal of Extra-Corporeal Technology, 2019, 51, 29-37.	0.2	2
1282	Reversal of anticoagulation in neurosurgical and neurocritical care settings. , 2022, , 239-266.		0
1283	Acute Stroke Treatment in an Anticoagulated Patient: When Is Thrombolysis an Option?. Current Treatment Options in Neurology, 2021, 23, 1.	0.7	1
1284	A cohort study on anticoagulant therapy risks in dental patients after multiple extractions. Minerva Dental and Oral Science, 2021, 70, 196-205.	0.5	2
1285	Molecular dynamic and pharmacological studies on proteinâ€œengineered hirudin variants of <i>Hirudinaria manillensis</i> and <i>Hirudo medicinalis</i>. British Journal of Pharmacology, 2022, 179, 3740-3753.	2.7	4
1286	<scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 2022, 38, 833-973.	0.5	8
1287	A three-step stacking capillary electrophoresis of field-amplified sample injection, sweeping, and micellar collapse for determination of dabigatran and its active metabolite in human plasma. Journal of Food and Drug Analysis, 2022, 30, 89-104.	0.9	1
1288	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circulation Journal, 2022, 86, 1790-1924.	0.7	49
1289	The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. Vascular Pharmacology, 2022, 144, 106994.	1.0	0
1293	Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism.. Blood Transfusion, 2021, , .	0.3	2
1297	Intracerebral hemorrhage and thrombin-induced alterations in cerebral microvessel matrix. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1732-1747.	2.4	3
1298	Anticoagulants: dose control methods and inhibitors. Obstetrics, Gynecology and Reproduction, 2022, 16, 158-175.	0.2	2
1299	â€œA case of...â€œ	0.0	0
1300	Consensus document of the Sociedad EspaÃ±ola de PatologÃa Digestiva on massive nonvariceal gastrointestinal bleeding and direct-acting oral anticoagulants. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	2
1301	New Anticoagulants for Stroke Prophylaxis in Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2012, 12, 287-294.	1.0	2
1303	Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients. Transplantation, 2022, 3, 208-218.	0.3	0
1304	Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants. Atherothrombosis, 2022, 12, 20-28.	0.1	1

#	ARTICLE	IF	CITATIONS
1305	Subchronic Toxicity Study of Alternanthera philoxeroides in Swiss Albino Mice Having Antioxidant and Anticoagulant Activities. <i>Journal of Toxicology</i> , 2022, 2022, 1-12.	1.4	2
1306	A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2016, 45, 98-105.	0.2	5
1308	Dabigatran etexilate is efficacious in consumptive coagulopathy and pain associated with venous malformations. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2023, 11, 397-403.e1.	0.9	2
1309	BLASKI I CIENIE WSPÅ“ÅCZESNEJ FARMAKOTERAPII ANTYKOAGULACYJNEJ. , 2016, 14, 64-72.		0
1311	Consensus Recommendations for Preventing and Managing Bleeding Complications Associated with Novel Oral Anticoagulants in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2013, 42, 593-602.	0.2	3
1312	ãf€ãf“ã,ãf^ãf©ãf³éžé†æœèè—ã«ã³4ãªMã,ãã,ãf€ãf«ã,ã,ããfžãf—ã®éªMè,,^ã†...æŠ•ã,ž1/4šè;€æ¼4;ããf€ãf“ã,ããfãf©ãf³æ;fã° ãã	0.0	0
1313	Oral Surgery in Patients Taking Direct Oral Anticoagulants (DOACs): A Practical Review of the Literature. <i>The Journal of Dentists</i> , 0, 7, 8-16.	0.1	0
1314	Comparative study of predisposition to thrombosis with administration of known systemic hemostatic agents and fibrin monomer in the experiment. <i>Bulletin of Siberian Medicine</i> , 2023, 21, 20-28.	0.1	0
1315	Which Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?. , 2013, , 275-282.		0
1316	Intravenous Dabigatran Provides Adequate Anticoagulation for Cardiopulmonary Bypass Using a Rabbit Model. <i>Anesthesiology</i> , 2023, 138, 523-532.	1.3	3
1317	An examination of causal associations and shared risk factors for diabetes and cardiovascular diseases in the East Asian population: A Mendelian randomization study. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
1318	Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects. <i>Pharmaceuticals</i> , 2023, 16, 364.	1.7	0
1319	Designing Smaller, Synthetic, Functional Mimetics of Sulfated Glycosaminoglycans as Allosteric Modulators of Coagulation Factors. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4503-4531.	2.9	3
1320	Challenges of Anticoagulant Therapy in Atrial Fibrillation“Focus on Gastrointestinal Bleeding. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6879.	1.8	4
1321	Ecarin-Based Methods for Measuring Thrombin Inhibitors. <i>Methods in Molecular Biology</i> , 2023, , 355-367.	0.4	0